

Sant P. Chawla, M.D.

CURRICULUM VITAE

PERSONAL INFORMATION:

Sant P. Chawla, M.D., FRACP

Sant P. Chawla M.D., Inc. (Medical Practice)

Sarcoma Oncology Center (Clinical Research Center)

2811 Wilshire Blvd., Suite 414, Santa Monica, CA 90403

Office Phone: (310) 552-9999; Office Fax: (310) 201-6685; Mobile: (310) 500-5391

Email: santchawla@sarcomaoncology.com

CURRENT POSITIONS:

Director, Sarcoma Oncology Center & Sant P. Chawla M.D., Inc.

2811 Wilshire Blvd #414, Santa Monica, CA 90403

CURRENT APPOINTMENTS AND AFFILIATIONS:

M.D. Anderson Cancer Center, <i>Adjunct Associate Professor</i> University of Texas, Houston, TX	2008-Present
UCLA David Geffen School of Medicine, <i>Assoc. Clinical Professor of Medicine</i> Los Angeles, CA	2004-Present
Cedars-Sinai Comprehensive Cancer Center, <i>Medical Oncologist</i> Los Angeles, CA	1998-Present
USC Keck School of Medicine, <i>Asst. Clinical Professor of Medicine</i> Los Angeles, CA	1998-Present
John Wayne Cancer Institute, <i>Adjunct Faculty, Medical Oncologist</i> Santa Monica, CA	1998-Present

PAST APPOINTMENTS AND AFFILIATIONS:

Stanford University Medical Center, <i>Adjunct Associate Professor</i> Palo Alto, CA	2011-2014
--	-----------

Sant P. Chawla, M.D.

UCLA-Santa Monica Hospital, <i>Director of Medical Oncology</i> Santa Monica ,CA	2004-2008
Midway Hospital Cancer Center, <i>Director of Medical Oncology</i> Los Angeles, CA	2004-2005
Century City Hospital Cancer Center, <i>Associate Director</i> Los Angeles, CA	1999-2005
Century City Hospital, <i>Director of Medical Oncology</i> Los Angeles, CA	1997-2007
Orthopaedic Hospital, <i>Director of Medical Oncology</i> Los Angeles, CA	1994-2008
UCLA David Geffen School of Medicine, <i>Asst. Clinical Professor of Medicine</i> Los Angeles, CA	1989-2004
Hospital of the Good Samaritan, <i>Director of Developmental Chemotherapy</i> Los Angeles, CA	1990-1996
Comprehensive Cancer Research Group, Co-Director of Cancer Research Cedars-Sinai Comprehensive Cancer Center	1990
M.D. Anderson Cancer Center <i>Asst. Professor of Medicine</i> <i>Melanoma / Sarcoma / Medical Gynecology / Oncology</i> University of Texas, Houston, TX	1986-1988
M.D. Anderson Cancer Center, <i>Asst. Internist</i> <i>Department of Medical Oncology</i> <i>University of Texas, Houston, TX</i>	1986-1988
Auckland Hospital, <i>Registrar Clinical Oncology</i> <i>Department of Oncology</i> <i>Auckland, New Zealand</i>	1980-1981

EDUCATION:

College: University of Rajasthan, <i>B.S. Premed</i> Jaipur, India	1970-1971
Medical School: All India Institute of Medical Sciences, <i>M.B.B.S.</i> New Delhi, India	1971-1975

Sant P. Chawla, M.D.

Rotating Internship: All India Institute of Medical Sciences New Delhi, India	1976
1st Yr Residency: Post Graduate Institute of Medical Sciences, <i>Internal Medicine</i> Chandigarh, India	1977
2nd-3rd Yr Residency: All India Institute of Medical Sciences, <i>Internal Medicine</i> New Delhi, India	1977-1980
Registrar: Auckland Hospital, <i>Medical Oncology</i> Auckland, New Zealand	1980-1981
Fellowship: M.D. Anderson Cancer Center, <i>Medical Oncology</i> University of Texas, Houston, TX	1981-1984
Fellow Royal Australasian College of Physicians, <i>F.R.A.C.P., Medical Oncology</i>	1980-1981

LICENSURE

Texas, License No. G-6917 (1984)
California, License No. A45088 (1988)

BOARD CERTIFICATIONS

American Board of Internal Medicine, 1985 (Valid Indefinitely)
American Board of Medical Oncology, 1987 (Valid Indefinitely)

TEACHING EXPERIENCE

Teach Residents and Students from UCLA School of Medicine at Orthopaedic Hospital	1992-Present
Teach Fellows, Residents and Students at Norris Cancer Center, USC Medical Center	1997-Present
Teach Fellows, Residents and Students at UCLA Medical Center	1988-Present
Teach Fellows, Residents and Students at Cedars-Sinai Medical Center, Department of Medicine	1988-Present
Taught Fellows, Residents and Students at	

Sant P. Chawla, M.D.

M.D. Anderson Cancer Center, Department of Gynecology 1985-1988

Taught House Staff and Students at
Auckland Hospital, New Zealand, Department of Medicine & Medical Oncology 1984-1981

Taught House Staff and Students at
All India Institute of Medical Sciences, Department of Medicine 1978-1979

SOCIETY MEMBERSHIPS

- **American Society of Clinical Oncology (Frequent Presenter)**
- **American Medical Association**
- **Los Angeles County Medical Association**
- **California Medical Association**
- **Connective Tissue Oncology Society**
- **Aiimsonians of America (Alumni Association of All India Institute of Medical Sciences)**
- **Indian Medical Association of Greater Los Angeles (Past President)**

RESEARCH ACTIVITIES

- **Developmental and Experimental Therapeutics**
- **Phase I – III Clinical Trials involving Molecular, Biological, Targeted-Gene Therapy and Anti- Neoplastics**
- **Phase IV Clinical Trials**

PUBLICATIONS & PRESENTATIONS

Peer-Reviewed Publications

1. Cell cycle checkpoint control: The cyclin G1/Mdm2/p53 axis emerges as a strategic target for broad-spectrum cancer gene therapy - A review of molecular mechanisms for oncologists. *Mol Clin Oncol.* 2018 Aug; 9(2): 115–134. Published online 2018 Jun 14. Doi: 10/3892/mco.2018.1657. Authors: Erlinda M. Gordon,, Joshua R. Ravicz, Seiya Liu, Sant P. Chawla, Frederick L. Hall

- 2. A multicenter phase II study of Q3 week or weekly paclitaxel in combination with bevacizumab for the treatment of metastatic or unresectable angiosarcoma.** *Rare Tumors*. 2018; 10: 2036361318771771. Published online 2018 Apr 23. doi: 10.1177/2037361318771771. Authors: Nam Bui, Nikhil Kamat, Vinod Ravi, Sant Chawla, Marti Lohman, and Kristen N Ganjoo
- 3. Eribulin therapy for the treatment of patients with advanced soft tissue sarcoma.** *Future Oncol*. 2018 Jul;14(16):1531-1545. doi: 10.2217/fo-2017-0461. Epub 2018 Feb 7. Authors: Seetharam M, Kolla KR, Chawla SP.
- 4. Activity of Eribulin in Patients With Advanced Liposarcoma Demonstrated in a Subgroup Analysis From a Randomized Phase III Study of Eribulin Versus Dacarbazine.** *J Clin Oncol*. 2017 Oct 20;35(30):3433-3439. doi: 10.1200/JCO.2016.71.6605. Epub 2017 Aug 30. Authors: Demetri GD, Schöffski P, Grignani G, Blay JY, Maki RG, Van Tine BA, Alcindor T, Jones RL, D'Adamo DR, Guo M, Chawla S.
- 5. Efficacy of Denosumab in Giant Cell Tumor of Bone: Results of an Open Label Phase 2 Study.** E. Palmerini, J-Y. Blay, A. Le Censne, P. Reichardt, P. Rutkowski, H. Gelderblom, R.J. Grimer, A. Feng, D. Jandial, S. Chawla. *Annals of Oncology*, Volume 28, Issue suppl_5, 1 September 2017, mdx440.071
- 6. Denosumab in advanced/unresectable giant-cell tumour of bone (GCTB): For how long?** *Eur J Cancer*. 2017 May;76:118-124. doi: 10.1016/j.ejca.2017.01.028. Epub 2017 Mar 17. Palmerini E, Chawla NS, Ferrari S, Sudan M, Picci P, Marchesi E, Leopardi MP, Syed I, Sankhala KK, Parthasarathy P, Mendanha WE, Pierini M, Paioli A, Chawla SP.
- 7. Doxorubicin plus evofosfamide versus doxorubicin alone in locally advanced, unresectable or metastatic soft-tissue sarcoma (TH CR-406/SARC021): an international, multicentre, open-label, randomised phase 3 trial.** *Lancet Oncol*. 2017 Aug;18(8):1089-1103. doi: 10.1016/S1470-2045(17)30381-9. Epub 2017 Jun 23. Authors: Tap WD, Papai Z, Van Tine BA, Attia S, Ganjoo KN, Jones RL, Schuetze S, Reed D, Chawla SP, Riedel RF, Krarup-Hansen A, Toulmonde M, Ray-Coquard I, Hohenberger P, Grignani G, Cranmer LD, Okuno S, Agulnik M, Read W, Ryan CW, Alcindor T, Del Muro XFG, Budd GT, Tawbi H, Pearce T, Kroll S, Reinke DK, Schöffski P.
- 8. Eribulin in advanced liposarcoma and leiomyosarcoma.** *Expert Rev Anticancer Ther*. 2017 Aug;17(8):717-723. doi: 10.1080/14737140.2017.1344098. Epub 2017 Jun 28. Authors: Setola E1, Noujaim J2, Benson C2, Chawla S3, Palmerini E4, Jones RL2.
- 9. Regin-G®, a tumor-targeted retrovector for malignant peripheral nerve sheath tumor: A case report.** *Mol Clin Oncol*. 2017 Jun;6(6):861-865. doi: 10.3892/mco.2017.1231. Epub 2017 Apr 28. Authors: Kim S, Federman N, Gordon EM, Hall FL, Chawla SP.
- 10. Results of a prospective phase 2 study of pazopanib in patients with advanced intermediate-grade or high-grade liposarcoma.** *Cancer* 2017.123:4640-4647. Brian L. Samuels MD, Sant P. Chawla MD, Neeta Somaiah MD, Arthur P. Staddon MD, Keith M. Skubitz MD, Mohammed M. Milhem MBBS, Pamela E. Kaiser MD, David C. Portnoy MD, Dennis A. Priebat MD, Mark S. Walker PhD, Edward J. Spreanski PhD
- 11. Current status and unanswered questions on the use of Denosumab in giant cell tumor of bone.** *Clin Sarcoma Res*. 2016 Sep 14;6(1):15. doi: 10.1186/s13569-016-0056-0. eCollection 2016. Authors:

Gaston CL, Grimer RJ, Parry M, Stacchiotti S, Dei Tos AP, Gelderblom H, Ferrari S, Baldi GG, Jones RL, Chawla S, Casali P, LeCesne A, Blay JY, Dijkstra SP, Thomas DM, Rutkowski P.

12. Trabectedin for Soft Tissue Sarcoma: Current Status and Future Perspectives. *Adv Ther.* 2016 Jul;33(7):1055-71. doi: 10.1007/s12325-016-0344-3. Epub 2016 May 27. Authors: Gordon EM, Sankhala KK, Chawla N, Chawla SP.

13. Eribulin versus dacarbazine in previously treated patients with advanced liposarcoma or leiomyosarcoma: a randomised, open-label, multicentre, phase 3 trial. *Lancet.* 2016 Apr 16;387(10028):1629-37. doi: 10.1016/S0140-6736(15)01283-0. Epub 2016 Feb 10. Authors: Schöffski P, Chawla S, Maki RG, Italiano A, Gelderblom H, Choy E, Grignani G, Camargo V, Bauer S, Rha SY, Blay JY, Hohenberger P, D'Adamo D, Guo M, Chmielowski B, Le Cesne A, Demetri GD, Patel SR.

14. Phase II study of amrubicin (SM-5887), a synthetic 9-aminoanthracycline, as first line treatment in patients with metastatic or unresectable soft tissue sarcoma: durable response in myxoid liposarcoma with TLS-CHOP translocation. *Invest New Drugs.* 2016 Apr;34(2):243-52. doi: 10.1007/s10637-016-0333-z. Epub 2016 Feb 20. Authors: Gupta S, Gouw L, Wright J, Chawla S, Pitt D, Wade M, Boucher K, Sharma S.

15. Tumor-targeting Salmonella typhimurium A1-R in combination with doxorubicin eradicate soft tissue sarcoma in a patient-derived orthotopic xenograft (PDOX) model. *Oncotarget.* 2016 Mar 15;7(11):12783-90. doi: 10.18632/oncotarget.7226. Authors: Murakami T, DeLong J, Eilber FC, Zhao M, Zhang Y, Zhang N, Singh A, Russell T, Deng S, Reynoso J, Quan C, Hiroshima Y, Matsuyama R, Chishima T, Tanaka K, Bouvet M, Chawla S, Endo I, Hoffman RM.

16. Ewing Sarcoma in a Patient With Cowden Syndrome. *J Natl Compr Canc Netw.* 2015 Nov;13(11):1310-4. Authors: Chandhanayingyong MC, Bernthal NM, Ungarreevittaya P, Nelson SD, Chawla SP, Singh AS.

17. First-line aldodoxorubicin vs doxorubicin in metastatic or locally advanced unresectable soft-tissue sarcoma: A phase 2b randomized clinical trial. *JAMA Oncology* Published online September 17, 2015, S.P. Chawla MD, Z. Papai MD, G. Mukhametshina MD, K. Sankala MD, L. Vasylyev MD, A. Fedenko MD, K. Khamly MD, K. Ganjoo MD, R. Nagarkar MD, S. Wieland PhD, D.J. Levitt MD

18. Hypertension (HTN) as a potential biomarker of efficacy in pazopanib-treated patients with advanced non-adipocytic soft tissue sarcoma. A retrospective study based on European Organisation for Research and Treatment of Cancer (EORTC) 62043 and 62072 trials. *Eur J Cancer.* 2015 Nov;51(17):2615-23. doi: 10.1016/j.ejca.2015.08.002. Epub 2015 Aug 25. Duffaud F, Sleijfer S, Litière S, Ray-Coquard I, Le Cesne A, Papai Z, Judson I, Schöffski P, Chawla SP, Dewji R, Marreaud S, Verweij J, van der Graaf WT.

19. Health-related quality-of-life results from PALETTE: A randomized, double-blind, phase 3 trial of pazopanib versus placebo in patients with soft tissue sarcoma whose disease has progressed during or after prior chemotherapy-a European Organization for research and treatment of cancer soft tissue and bone sarcoma group global network study (EORTC 62072). *Cancer.* 2015 Sep 1;121(17):2933-41. doi: 10.1002/ncr.29426. Epub 2015 May 29. Authors: Coens C, van der Graaf WT,

Blay JY, Chawla SP, Judson I, Sanfilippo R, Manson SC, Hodge RA, Marreaud S, Prins JB, Lugowska I, Litière S, Bottomley A.

20. Giant-cell tumor of bone: treatment options and role of denosumab. *Biologics*. 2015 Jul 14;9:69-74. doi: 10.2147/BTT.S57359. eCollection 2015. Authors: Singh AS, Chawla NS, Chawla SP.

21. Ombrabulin plus cisplatin versus placebo plus cisplatin in patients with advanced soft-tissue sarcomas after failure of anthracycline and ifosfamide chemotherapy: a randomised, double-blind, placebo-controlled, phase 3 trial. *Lancet Oncol*. 2015 May;16(5):531-40. doi: 10.1016/S1470-2045(15)70102-6. Epub 2015 Apr 8. Authors: Blay JY, Pápai Z, Tolcher AW, Italiano A, Cupissol D, López-Pousa A, Chawla SP, Bompas E, Babovic N, Penel N, Isambert N, Staddon AP, Saâda-Bouزيد E, Santoro A, Franke FA, Cohen P, Le-Guenec S, Demetri GD.

22. A phase 1B/2 study of aldoxorubicin in patients with soft tissue sarcoma. *Cancer*. 2015 Feb 15;121(4):570-9. doi: 10.1002/cncr.29081. Epub 2014 Oct 13. Authors: Chawla SP, Chua VS, Hendifar AF, Quon DV, Soman N, Sankhala KK, Wieland DS, Levitt DJ.

23. Tumor Hypoxia is a Therapeutic Target in Soft Tissue Sarcoma. *Cancer Discovery*. Published Online First September 11, 2014;doi:10.1158/2159-8290.CD-RW2014-193. Chawla SP, Crammer LD, Van Tine BA, Reed DR, Okuno SH, Butrynski JE et al.

24. Prognostic value of necrosis after neoadjuvant therapy for soft tissue sarcoma. *J Surg Oncol*. 2015 Feb;111(2):152-7. doi: 10.1002/jso.23775. Epub 2014 Aug 30. Authors: Vaynrub MI, Taheri N, Ahlmann ER, Yao C, Fedenko AN, Allison DC, Chawla SP, Menendez LR.

25. Phase II Study of the Safety and Antitumor Activity of the Hypoxia-Activate Prodrug TH-302 in Combination With Doxorubicin in Patients With Advanced Soft Tissue Sarcoma. *J Clin Oncol* 32 : 2014. Authors: Sant P Chawla, Sarcoma Oncology Center, Santa Monica, CA; Lee D. Cramer, University of Arizona Cancer Center, Tucson, Az; Brian A van Tine and Douglas R. Adkins, Washington University in St Louis, St Louis, MO; Damon R. Reed, Moffitt Cancer Center and Research Institute, Tampa, FL; Scott H.Okuno, Mayo Clinic , Rochester, MN; James E. Butrynski, Dana Farber Cancer Institute, Boston, MA; Kristen N, Ganjoo, Stanford University Medical Center, Stanford , CA. Andrew E. Hendifar, Cedars Sinai Hospital , Los Angeles, CA; Stew Kroll, Threshold Pharmaceuticals, South San Francisco;

26. Pazopanib in uterine sarcoma (UtS): Review of two European Organisation for Research and Treatment of Cancer (EORTC) and GSK clinical trials 62043 and 62072 on pazopanib for soft tissue sarcoma (STS). *J Clin Oncol* 32:5s, 2014. Authors: Isabelle Laure Ray-Coquard, Stefan Sleijfer, Saskia Litière, Jean-Yves Blay, Axel Le Cesne, Zsuzsanna Papai, Ian Robert Judson, Patrick Schoffski, Sant P. Chawla, Thierry Gil, Sophie Piperno-Neumann, Sandrine Marreaud, Rachel Hodge, Winette T.A. Van Der Graaf; Centre Léon Bérard, Lyon, France; Erasmus MC Cancer Institute, Department of Medical Oncology and Cancer Genomics Netherlands, Rotterdam, Netherlands; European Organisation for Research and Treatment of Cancer, Brussels, Belgium; Institut Gustave Roussy, Villejuif, France; Oncology Department, State Health Center, Budapest, Hungary; The Royal Marsden NHS Foundation Trust, London, United Kingdom; Laboratory of Experimental Oncology and Department of General Medical Oncology, KU Leuven and University Hospitals, Leuven, Belgium; Sarcoma Oncology Center, Santa Monica, CA; Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium; Institut Curie,

Sant P. Chawla, M.D.

Paris, France; GlaxoSmithKline Oncology, Uxbridge, United Kingdom; Department of Medical Oncology, Radboud University Medical Center, Nijmegen, Netherlands.

27. Response to treatment with denosumab in patients with giant cell tumor of bone (GCTB): FDG PET results from two phase 2 trials. *J Clin Oncol* 32:5s, 2014. Authors: Keith M. Skubitz, David Morgan Thomas, Sant P. Chawla, Arthur P. Staddon, Jacob Engellau, Amy Feng, Bruce A. Bach; University of Minnesota, Minneapolis, MN; Peter MacCallum Cancer Centre, Melbourne, Australia; Sarcoma Oncology Center, Santa Monica, CA; Pennsylvania Oncology Hematology Associates, Philadelphia, PA; Skåne University Hospital, Lund, Sweden; Amgen Inc., Thousand Oaks, CA; Amgen, Inc., Thousand Oaks, CA.

28. Low-dose gemcitabine doxorubicin and docetaxel combination in patients with advanced/unresectable/metastatic sarcoma who failed prior chemotherapy: Updated analysis. *J Clin Oncol* 32:5s, 2014. Authors: Vivek Narasimhan, James Hu, Kamallesh Kumar Sankhala, Doris V. Quon, Lawrence Menendez, Lita Fernandez, Victoria S Chua, Sant P. Chawla; Sarcoma Oncology Center, Santa Monica, CA; USC Norris Comprehensive Cancer Center, Los Angeles, CA.

29. Randomized phase 2b trial comparing first-line treatment with aldoxorubicin versus doxorubicin in patients with advanced soft tissue sarcomas. *J Clin Oncol* 32:5s, 2014. Authors: Sant P. Chawla, Zsuzsanna Papai, Kamallesh Sankhala, Leonid Vasylyev, Guzel Mukhametsina, Mamed Aliev, Kenneth Khamly, Scott Wieland, Daniel J. Levitt; Sarcoma Oncology Center, Santa Monica, CA; Oncology Department, State Health Center, Budapest, Hungary; CTCRC Institute for Drug development, San Antonio, TX; Institute of Medical Radiology, Kharkiv, Ukraine; State Healthcare Institute Republican Clinical Oncological Center of the Ministry of Health of the Republic of Tatarstan, Kazan, Russia; Blokhin Cancer Research Center, Moscow, Russia; Epworth Healthcare and Clinical Trials Research Centre, Richmond, Australia; CytRx Corporation, Los Angeles, CA.

30. 14-day continuous infusion ifosfamide in advanced refractory sarcomas. *J Clin Oncol* 32:5s, 2014. Authors: Arun S. Singh, Kamallesh Kumar Sankhala, Arnob Mukherjee, Vivek Narasimha, Bartosz Chmielowski, Doris V. Quon, Vicky Chua, Sant P. Chawla; University of California Los Angeles Medical Center, Santa Monica, CA; Sarcoma Oncology Center, Santa Monica, CA; School of Medicine/Translational Oncology Research Laboratory, University of California, Los Angeles, Los Angeles, CA:

31. Anticancer activity of the type I insulin-like growth factor receptor antagonist, ganitumab, in combination with the death receptor 5 agonist, conatumumab. *Target Oncol.* 2014 May 11. [Epub ahead of print]. Authors: Taberero J, Chawla SP, Kindler H, Reckamp K, Chiorean EG, Azad NS, Lockhart AC, Hsu CP, Baker NF, Galimi F, Beltran P, Baselga J.

32. A phase 2 trial of R1507, a monoclonal antibody to the insulin-like growth factor-1 receptor (IGF-1R), in patients with recurrent or refractory rhabdomyosarcoma, osteosarcoma, synovial sarcoma, and other soft tissue sarcomas: Results of a Sarcoma Alliance for Research Through Collaboration study. *Cancer.* 2014 May 2. doi: 10.1002/cncr.28728. [Epub ahead of print]. Pappo AS, Vassal G, Crowley JJ, Bolejack V, Hogendoorn PC, Chugh R, Ladanyi M, Grippo JF, Dall G, Staddon AP, Chawla SP, Maki RG, Araujo DM, Georger B, Ganjoo K, Marina N, Blay JY, Schuetze SM, Chow WA, Helman LJ.

- 33. Randomised phase III trial of trabectedin versus doxorubicin-based chemotherapy as first-line therapy in translocation-related sarcomas.** *Eur J Cancer.* 2014 Apr;50(6):1137-47. doi: 10.1016/j.ejca.2014.01.012. Epub 2014 Feb 7. Authors: Blay JY, Leahy MG, Nguyen BB, Patel SR, Hohenberger P, Santoro A, Staddon AP, Penel N, Piperno-Neumann S, Hendifar A, Lardelli P, Nieto A, Alfaro V, Chawla SP.
- 34. A Phase II multicenter, open-label, clinical and pharmacokinetic trial of PM00104 in patients with advanced Ewing Family of Tumors.** *Invest New Drugs.* 2014 Feb;32(1):171-7. doi: 10.1007/s10637-013-0037-6. Epub 2013 Nov 1. Authors: Jones RL, Ferrari S, Blay JY, Navid F, Lardelli P, Alfaro V, Siguero M, Soman N, Chawla SP.
- 35. Giant cell tumor of bone in childhood: clinical aspects and novel therapeutic targets.** *Paediatric Drugs.* 2014 Feb;16(1):21-8. doi: 10.1007/s40272-013-0051-3. Authors: Federman N, Brien EW, Narasimhan V, Dry SM, Sodhi M, Chawla SP.
- 36. A Phase II multicenter, open-label, clinical and pharmacokinetic trial of PM00104 in patients with advanced Ewing Family of Tumors.** *Invest New Drugs. November 01 2013.* Authors: Jones, R. L., Ferrari, S., Blay, J. Y., Navid, F., Lardelli, P., Alfaro, V., Siguero, M., Soman, N. Chawla, Sant.
- 37. Giant Cell Tumor of Bone in Childhood: Clinical Aspects and Novel Therapeutic Targets.** *Pediatric Drugs (2013): 1-8, October 10, 2013.* Authors: Noah Federman, Earl W. Brien, Vivek Narsimhan, Sarah M. Dry, Monish Sodhi, Sant Chawla.
- 38. Trabectedin is a feasible treatment for soft tissue sarcoma patients regardless of patient age: a retrospective pooled analysis of five phase II trials.** *Br J Cancer.* 2013 Oct 1;109(7):1717-24. doi: 10.1038/bjc.2013.524. Epub 2013 Sep 10. Authors: Cesne AL, Judson I, Maki R, Grosso F, Schuetze S, Mehren MV, Chawla SP, Demetri GD, Nieto A, Tanovic A, Blay JY.
- 39: Weekly nab-Rapamycin in patients with advanced nonhematologic malignancies: final results of a phase I trial.** *Clin Cancer Res.* 2013 Oct 1;19(19):5474-84. doi: 10.1158/1078-0432.CCR-12-3110. Gonzalez-Angulo AM, Meric-Bernstam F, Chawla S, Falchook G, Hong D, Akcakanat A, Chen H, Naing A, Fu S, Wheler J, Moulder S, Helgason T, Li S, Elias I, Desai N, Kurzrock R.
- 40. Ridaforolimus in advanced or metastatic soft tissue and bone sarcomas.** *Expert Review of Clinical Pharmacology, September 2013.* Authors: Mita, M. M., Gong, J, Chawla, Sant.
- 41. Safety and efficacy of denosumab for adults and skeletally mature adolescents with giant cell tumour of bone: interim analysis of an open-label, parallel-group, phase 2 study.** *The Lancet Oncology, Volume 14, Issue 9, Pages 901 - 908, August 2013.* Authors: Sant Chawla, Robert Henshaw, Leanne Seeger, Edwin Choy, Jean-Yves Blay, Stefano Ferrari, Judith Kroep, Robert Grimer, Peter Reichardt, Piotr Rutkowski, Scott Schuetze, Keith Skubitiz, Arthur Staddon, David Thomas, Yi Qian, Ira Jacobs.
- 42. Results of an international randomized phase III trial of the mammalian target of rapamycin inhibitor ridaforolimus versus placebo to control metastatic sarcomas in patients after benefit from prior chemotherapy.** *J Clin Oncol.* 2013 Jul 1;31(19):2485-92. doi: 10.1200/JCO.2012.45.5766. Epub 2013 May 28. Demetri GD, Chawla SP, Ray-Coquard I, Le Cesne A, Staddon AP, Milhem MM, Penel N,

Riedel RF, Bui-Nguyen B, Cranmer LD, Reichardt P, Bompas E, Alcindor T, Rushing D, Song Y, Lee RM, Ebbinghaus S, Eid JE, Loewy JW, Haluska FG, Dodion PF, Blay JY.

43. Results of a phase I dose escalation study of eltrombopag in patients with advanced soft tissue sarcoma receiving doxorubicin and ifosfamide. Chawla SP, Staddon A, Hendifar A, Messam CA, Patwardhan R, Kamel YM. *BMC Cancer*. 2013 Mar 16;13:121. doi: 10.1186/1471-2407-13-121.

44. Anti-cancer activity of the type I insulin-like growth factor receptor antagonist, ganitumab, in combination with the death receptor 5 agonist, conatumumab. *Molecular Cancer Therapeutics*, February 2013. Authors: Joseph Tabenero, Sant P. Chawla, Hedy Kindler, Karen Reckamp, E. Gabriela Chiorean, Nilofer S. Azad, A. Craig Lockhart, Cheng-Pang Hsu, Nigel F. Baker, Francesco Galimi, Pedro Beltran, Jose Baselga.

45. Growth modulation index as metric of clinical benefit assessment among advanced soft tissue sarcoma patients receiving trabectedin as a salvage therapy. *Ann Oncol*. 2013 Feb;24(2):537-42. doi: 10.1093/annonc/nds470. Epub 2012 Nov 1. Penel N, Demetri GD, Blay JY, Cousin S, Maki RG, Chawla SP, Judson I, von Mehren M, Schöffski P, Verweij J, Casali P, Rodenhuis S, Schütte HJ, Cassar A, Gomez J, Nieto A, Zintl P, Pontes MJ, Le Cesne A.

46. Phase I study to assess the pharmacokinetics and the effect on cardiac repolarization of amrubicin and amrubicinol in patients with advanced solid tumors. *Cancer Chemotherapy and Pharmacology: Volum 71, Issue 4 (2013), Page 1083-1094*. Authors: Nianhang Chen, Sant P. Chawla, Elena Gabriela Chiorean, William L. Read, Mayer Gorbaty, Alain C. Mita, Lotus Yung, Peter Bryan, Richard McNally, Markus F. Renschler, Sunil Sharma.

47. Clinical effect of denosumab treatment on giant cell tumor of bone (GCTB). *Lancet Oncology*, February 2013. Authors: Sant Chawla, Robert Henshaw, Leanne Seeger, Edwin Choy, Jean-Yves Blay, Stefano Ferrar, Judith Kroep, Robert Grimer, Peter Reichardt, Piotr Rutkowski, Scott Schuetze, Keith Skubitz, Arthur Staddon, David Thomas, Yi Qian, Ira Jacobs.

48. Phase I dose escalation study of eltrombopag in patients with advanced soft tissue sarcoma receiving doxorubicin and ifosfamide. *BioMed Central*, March 2013. Authors: Sant P. Chawla, Arthur Staddon, Andrew Hendifar, Conrad A. Messam, Rita Patwardhan, Yasser Mostafa Kamel.

49. Moving Beyond Response Criteria: New Measures of Success in the Treatment of Sarcomas. *Current Treatment Options in Oncology, Online FirstTM*, 30 May 2012. Authors: Andrew E. Hendifar, Elke Ahlmann, Daniel C. Allison, James Hu, Lawrence Menendez, Sant P. Chawla.

50. Seguridad y eficacia de denosumab en el tumor de células gigantes de hueso (TCG): análisis interino de un ensayo de fase 2. *2o Simposio Nacional de la SEOM, Madrid 24 – 26 Octubre 2012*. Authors: J. Martin Broto (1), J. Y. Blay (2), S. P. Chawla (3), E. Choy (4), M. Dominkus (5), J. Engellau (6), R. Grimer (7), R. M. Henshaw (8), Y. Qian (9), I. A. Jacobs (9).

51. Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial. *Lancet*. 2012 May 19;379(9829):1879-86. doi: 10.1016/S0140-6736(12)60651-5. Epub 2012 May 16. van der Graaf WT, Blay JY, Chawla SP, Kim DW, Bui-Nguyen B, Casali PG, Schöffski P, Aglietta M, Staddon AP, Beppu Y, Le Cesne A, Gelderblom H,

Judson IR, Araki N, Ouali M, Marreaud S, Hodge R, Dewji MR, Coens C, Demetri GD, Fletcher CD, Dei Tos AP, Hohenberger P; EORTC Soft Tissue and Bone Sarcoma Group; PALETTE study group.

52. A Meta- Analysis of Osteosarcoma Outcomes in the Modern Medical Era. *Sarcoma, March, 2012.* Daniel C. Allison, Scott C. Carney, Elke R. Ahlmann, Andrew Hendifar, Sant Chawla, Alex Fedenko, Constance Angeles, and Lawrence R. Menendez.

53. First-line treatment of metastatic or locally advanced unresectable soft tissue sarcomas with conatumumab in combination with doxorubicin or doxorubicin alone: A Phase I/II open-label and double-blind study. *Eur J Cancer. 2012 Jan 10.* Authors: Demetri GD, Le Cesne A, Chawla SP, Brodowicz T, Maki RG, Bach BA, Smethurst DP, Bray S, Hei YJ, Blay JY.

54. Phase II study of the mammalian target of rapamycin inhibitor ridaforolimus in patients with advanced bone and soft tissue sarcomas. *J Clin Oncol. 2012 Jan 1;30(1):78-84.* Authors: Chawla SP, Staddon AP, Baker LH, Schuetze SM, Tolcher AW, D'Amato GZ, Blay JY, Mita MM, Sankhala KK, Berk L, Rivera VM, Clackson T, Loewy JW, Haluska FG, Demetri GD.

55. R1507, a monoclonal antibody to the insulin-like growth factor 1 receptor, in patients with recurrent or refractory Ewing sarcoma family of tumors: results of a phase II Sarcoma Alliance for Research through Collaboration study. *J Clin Oncol. 2011 Dec 1;29(34):4541-7.* Authors: Pappo AS, Patel SR, Crowley J, Reinke DK, Kuenkele KP, Chawla SP, Toner GC, Maki RG, Meyers PA, Chugh R, Ganjoo KN, Schuetze SM, Juergens H, Leahy MG, Geoerger B, Benjamin RS, Helman LJ, Baker LH.

56. Treatment approaches to sarcoma in the community setting. *Clin Adv Hematol Oncol. 2011 Jun;9(6):460-1.* Author: Chawla S.P.

57. A phase I study of the safety and pharmacokinetics of the hypoxia-activated prodrug TH-302 in combination with doxorubicin in patients with advanced soft tissue sarcoma. *Oncology. 2011;80(1-2):50-6* Authors: Ganjoo KN, Cranmer LD, Butrynski JE, Rushing D, Adkins D, Okuno SH, Lorente G, Kroll S, Langmuir VK, Chawla SP.

58. Pathotropic targeting advances clinical oncology: Tumor-targeted localization of therapeutic gene delivery. *Oncology Reports (2010) 24, 829-833.* Authors: Hall, F.L., Levy J.P., Reed R.A, Petchpud, W.N., Chua V.S., Chawla S.P., Gordon E.M.

59. Advanced Phase I/II Studies of Targeted Gene Delivery In Vivo: Intravenous REXIN-G for Gemcitabine-resistant Metastatic Pancreatic Cancer. *Molecular Therapy, (2010) 18 2, 435– 441.* doi:10.1038/mt.2009.228. Authors: Chawla S.P., Chua V.S., Fernandez L., Quon D., Blackwelder W.C., Gordon E.M., Hall F.L.

60. Prevention of chemotherapy induced nausea and vomiting: a focus on aprepitant. *Expert Opin Drug Metab Toxicol. 2009 Dec;5(12):1607-14.* doi: 10.1517/17425250903451675. Review. Sankhala KK, Pandya DM, Sarantopoulos J, Soefje SA, Giles FJ, Chawla SP.

61. Phase I/II and phase II studies of targeted gene delivery in vivo: intravenous REXIN-G for chemotherapy-resistant sarcoma and osteosarcoma. *Mol Ther. 2009 Sep;17(9):1651-7.* doi: 10.1038/mt.2009.126. Epub 2009 Jun 16. Chawla SP, Chua VS, Fernandez L, Quon D, Saralou A, Blackwelder WC, Hall FL, Gordon EM.

- 62. Efficacy and Safety of Trabectedin in Patients With Advanced or Metastatic Liposarcoma or Leiomyosarcoma After Failure of Prior Anthracyclines and Ifosfamide: Results of a Randomized Phase II Study of Two Different Schedules.** Authors: Demetri G.D., Chawla S., et al: *Journal of Clinical Oncology*, Vol 27, No 25 (September 1), 2009: pp. 4188-4196.
- 63. Clinical Case Review: Desmoplastic Small Round Cell Tumor: Current Treatment Approach and Role of Targeted Therapy.** *Clin Adv Hematol Oncol.* 2009 Jul;7(7):476-8. Authors: Sankhala, K.K., Chawla S.P.
- 64. F-18 FDG PET and PET/CT evaluation of response to chemotherapy in bone and soft tissue sarcomas.** *Clin Nucl Med.* 2008 Jan;33(1):8-13. Iagaru A, Masamed R, Chawla SP, Menendez LR, Fedenko A, Conti PS.
- 65. Perifosine as an active agent in the treatment of patients with advanced sarcoma.** *ASCO-Journal of Clinical Oncology.* Vol 25, No. 18S (June 20, 2007 Supplement), 2007: 10059. Authors: Birch R., Chawla S.P., Sarcoma Oncology Center.
- 66. Yondelis Sarcoma Study Group. Randomized Phase II study of Trabectedin in patients with Liposarcoma and Leiomyosarcoma after failure of prior anthracyclines (A) and Ifosfamide (I).** *ASCO-Journal of Clinical Oncology.* Vol 25, No. 18S (June 20, 2007 Supplement), 2007: 10060. Authors: Morgan J. A., Le Cesne A., Chawla S.P., Mehren M. Von, Schuetze S., Casali P.G., Nieto A., Elsayed Y., Izquierdo M. A. and Demetri G.
- 67. Survival results with AP23573, a novel mTOR inhibitor, in patients with advanced soft tissue or bone sarcomas: Update of phase II trial.** *ASCO-Journal of Clinical Oncology.* Vol 25, No. 18S (June 20, 2007 Supplement), 2007:10076. Authors: Chawla S.P., Tolcher A. W., Staddon A. P., Schuetze S., D'Amato G. Z., Blay J. Y., Loewy J., Kan R. and Demetri G. D., Century City Doctor's Hospital.
- 68. Effects of Denosumab in the treatment of Giant Cell Tumor of Bone: Preliminary results from an open-label phase 2 study.** *CTOS 2007. 2004015 study. Aspire ID 1-V7VJ.* June 18, 2007. Authors: Thomas D., Chawla S.P., Skubitz K., Smith J., Ye Z., Jun S.
- 69. AP23573 Sarcoma Phase II Trials, a novel mTOR inhibito, in patients (pts) with advanced soft tissue or bone sarcomas.** *Journal of Clinical Oncology*, Vol 24, No. 18S (June 20 Supplement), 2006: 9505. Authors: Chawla S.P., A.W. Tolcher, A.P. Staddon, S.M. Schuetze, G.Z. D'Amato, J.Y. Blay, K.K. Sankhala, S.T. Daly, V.M. Rivera, G.D. Demetri.
- 70. AP23573: A Review of Recent Results, AP23573 is a targeted cancer therapy that inhibits the activity of mTOR, a cellular enzyme that plays a key role in cell growth and proliferation.** *The Liddy Shriver Sarcoma Initiative, Newsletter Vo3 No4*, http://www.liddyshriversarcomainitiative.org/Newsletters/V02_N04/AP23573/ap23573.htm, copyright 2005. Authors: Chawla S.P., Sankhala K. K., Century City Doctors Hospital.
- 71. The oral neurokinin-1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a multinational, randomized, double-blind, placebo-controlled trial in patients receiving high-dose cisplatin--the Aprepitant Protocol 052 Study Group.** *J Clin Oncol.* 2003 Nov 15;21(22):4112-9. Epub 2003 Oct 14. Hesketh PJ, Grunberg SM, Gralla RJ, Warr DG, Roila F, de

Wit R, Chawla SP, Carides AD, Ianus J, Elmer ME, Evans JK, Beck K, Reines S, Horgan KJ; Aprepitant Protocol 052 Study Group.

72. Establishing the dose of the oral NK1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting. *Cancer*. 2003 May 1;97(9):2290-300. Chawla SP, Grunberg SM, Gralla RJ, Hesketh PJ, Rittenberg C, Elmer ME, Schmidt C, Taylor A, Carides AD, Evans JK, Horgan KJ.

73. Establishing the Dose of MK-0869, an Oral NK1 Antagonist, for the Prevention of Chemotherapy-Induced Nausea and Emesis. *Cancer* 2003; 97:2290-300. Authors: S.P. Chawla, S.M. Grunberg, R.J. Gralla et al.

74. The Oral Neurokinin-1 Antagonist Aprepitant for the Prevention of Chemotherapy- Induced Nausea and Vomiting: A Multinational, Randomized, Double-Blind, Placebo- Controlled Trial in Patients Receiving High Dose Cisplatin- The Aprepitant Protocol 052 Study Group. *Journal of Clinical Oncology*, Vol.21, No 22, #4112- 4119, (November 15) 2003. Authors: P.J. Hesketh, S.M. Grunberg, R.J. Gralla, D.G. Warr, F. Roila, R.D. Wit, S.P. Chawla, et.al.

75. Systemic irinotecan and regional floxuridine after hepatic cytoreduction in 185 patients with unresectable colorectal cancer metastases. *Ann Surg Oncol*. 2002 Mar;9(2):148-55. Litvak DA, Wood TF, Tsioulis GJ, Chung M, Chawla SP, Foshag LJ, Morton DL, Ramming KP, Bilchik AJ.

76. Primary chemotherapy for Osteosarcoma with systemic adriamycin and intra-arterial cisplatin. *Cancer Bulletin*, vol 42:5, 314-317, 1990. Authors: Benjamin R. S., Chawla S.P., Carrasco C.H., Raymond A. K., Murray J. A., and Armen T. O.

77. Osteosarcoma of the Head and Neck. *Cancer Bulletin*, vol 42:5, 347-354, 1990. Authors: Geopfert H., Raymond A. K., Spires J. R., Chawla S.P., Wolf P. F., Lee Y., and Batsakis, J.G.

78. Osteosarcoma: Angiographic Assessment of Response to Preoperative Chemotherapy. *Radiology* 170:839-342, 1989. Authors: Carrasco C. H., Claringsangarej C. O., Raymond A. K., Richli W. R., Wallace S., Chawla S.P., Ayala A. G.

79. Recovery of Sperm Production After Chemotherapy for Osteosarcoma. *Cancer*, 63:2115-2123, 1989. Authors: Meistrick M. L., Chawla S.P., Da Cunha M. F., Johnson S. L., Plager C., Papadopoulos N. E., Lipsultz L. I., Benjamin R. S.

80. Smooth Muscle Neoplasms of the Uterus other than Ordinary Leiomyosarcoma. A Study of 46 cases with Emphasis on Diagnostic Criteria and Prognostic Factors. *Cancer*, 62:2239-2247, 1988. Authors : Evans H. L., Chawla S.P., Simpson C., Finn K. P.

81. Phase I Study of Weekly-Administered Iproplatin [Cisdichloro-transdihydroxy-bis-isoprophylamine platin (chip, JM9)]. *Investigational New Drugs G*:311-317, 1988. Authors: Chawla S.P., Yap B. S., Tenny D. M., Bodey G. P. and Benjamin R. S.

82. Aberrant Oncogene Expression in Uncultured Human Sarcoma and Melanoma. *Anticancer Research* 7:1117-1124, 1987. Authors: Shin D. M., Gupta V., Ludvik D. , Chawla S.P., Benjamin S., Gutterman J. and Blick M.

- 83. Clinical Evaluation of Recombinant Interferon alfa-2A (Roferon-A) in Metastatic Melanoma using Two Different Schedules.** *J. Clin Oncol* 5:1240-1246, 1987. Authors: Legha S. S., Papadopoulos N. E. J., Plager C., Ring S., Chawla S.P., Evans L. M., Benjamin R. S.
- 84. A Randomized trial in Postmenopausal patients with Advanced Breast Cancer Comparing endocrine and Cytotoxic Therapy Given Sequentially or in Combination.** *J. Clin Oncol.* 4:186-193, 1986. Authors: Chawla S.P., (Australian and New Zealand Breast Cancer Trial Group).
- 85. Chondro-sarcoma with Additional Mesenchymal component (“de-differentiated Chondrosarcoma) Part I: A Clinicopathological study of 26 cases.** *Cancer* 58:278-286, 1986. Authors: Johnson S., Tetu B., Ayala A. G., and Chawla S.P.
- 86. A randomized trial in postmenopausal patients with advanced breast cancer comparing endocrine and cytotoxic therapy given sequentially or in combination.** By the Australian and New Zealand Breast Cancer Trial Group, Clinical Oncology Society of Australia. *J. Clin Oncol.* 4:186-193, 1986. Authors: Schwartz M., Chawla S.P., Harvey V., Kay R., Mak D., Manson B., Probert J., Stephens E., Wood H., et al.
- 87. Phase II Studies of homoharringtone in patients with advanced malignant melanoma; sarcoma; head and neck, breast and colorectal carcinomas.** *Cancer Treatment Reports* 70:375-379, 1986. Authors: Dajani J. A., Dimery I., Chawla S.P., Pinnamaneni K., Benjamin R. S., Legha S. S., and Krakoff I. H.
- 88. Limb-salvage surgery in osteosarcoma: Early experience at MD Anderson Hospital and Tumor Institute.** *Cancer Treatment Symposia* 3:131-137, 1985. Authors: Murray J. A., Jesspu K., Romsdahl M., Raymond K., Ayala A., Carrasco H., Wallace S., Jaffe N., Benjamin R., Plager C., Papadopoulos N., and Chawla S.P.
- 89. Evaluation of Novantrone Cardiac Toxicity by Nuclear Angiography and endomyocardial biopsy: An update.** *Proceedings of the Current Status of Novantrone.* Pp 69- 73, 1985. Authors: Benjamin R. S., Holmes F., Chawla S.P., Ewer M. S., Carrasco C. H., Mackay B., Dukart G., and Bodey G. P.
- 90. Detorubicin - An active anthracycline in untreated metastatic melanoma.** *J. Clin Oncol* 3:1529-1534, 1985. Authors: Chawla S.P., Legha S. S., and Benjamin R. S.
- 91. Malignant Fibrous Histiocytoma of Jaws: A Clinicopathologic study of eleven cases.** *Cancer* 56:1590-1596, 1985. Authors: Abdul-Karim F. W., Ayala A. G., Chawla S.P., Jing B. S., Geopfert H.
- 92. Evaluation of Mitoxantrone cardiac toxicity by nuclear angiography and endomyocardial biopsy: An update.** *Invest New Drug* 3:117-121, 1985. Authors: Benjamin R. S., Chawla S.P., Ewer M. S., Carrasco C. H., Mackay B., and Holmes F.
- 93. Tumor-associated fever in breast cancer.** *Cancer* 53:1596-1599, 1984. Authors: Chawla S.P., Buzdar A., Hortobagyi G., and Blumenschein G.

Sant P. Chawla, M.D.

58. A judicious approach to limb salvage. *Cancer Bulletin* 36:32-36, 1984. Authors: Benjamin R. S., Murray J. A., Wallace S., Ayala A., Chawla S.P., Raymond A. K., Carrasco C. H., Romsdahl M. M., Papadopoulos N. E. J., and Plager C.

94. High cumulative dose Adriamycin beyond the conventional limits of 500 mg/m² and reduction of cardiotoxicity by continuous infusion schedule (eds, Spitzky K. H. and Karrer K.). *13th International Congress of Chemotherapy, Vienna, Austria. Verlag H. Egermann, 1983, pp. 546-550.* Authors: Chawla S.P., Benjamin R. S., Ewer M.S., Hortobagyi G. N., Legha S. S., Mackay B., Ali M. K., Carrasco C. H., Wallace S., Haynie III T. P., and Freireich E. J.

95. Role of cardiac biopsy and radionuclide scan in monitoring of adriamycin-induced cardiotoxicity, (eds, Spitzky K. H. and Karrer K.). *13th International Congress of Chemotherapy, Vienna, Austria. Verlag H. Egermann, 1983, pp. 490-492.* Authors: Chawla S.P., Benjamin R. S., Legha S. S., Ewer M. S., Ali M. D., Mackay, B., Carrasco C. H., Hortobagyi G. N., Wallace S. Haynie III T. P., and Freireich E. J.

Books and Chapter(s) Publications

1. Cisplatin and Adriamycin as Neoadjuvant and Adjuvant Chemotherapy in the management of Soft Tissue Sarcoma. *Adjuvant therapy of Cancer VI, 1990.* Authors: Chawla S.P., Rosen G., Eilber F., Lowenbraun S., Eckardt J., Morton D. L., Selch M., Greenberg S. And Mirra J.

2. Preoperative intra-arterial cisplatin and limb salvage surgery for patients with high grade osteosarcoma of the extremities. *IN: Adjuvant Therapy of Cancer V. (ed, Salmon S. E.), Grune & Stratton, Florida, 1987, pp 701-710.* Authors: Chawla S.P., Benjamin R. S., Jaffe N., Carrasco C. H., Raymond A. K., Ayala A. G., Wallace S., Armen T., Papadopoulos N. E. J., Plager C., Murray J. A.:

3. Adjuvant immunotherapy with Newcastle disease viral oncolysate. *IN: Adjuvant therapy of Cancer V (ed, Salmon S. E.), Grune & Stratton, Florida, 1987, pp 657-663.* Authors: Plager C., Bowen J. M., Fenoglio C. J., Papadopoulos N. E. J., Murray L., Chawla S.P., Benjamin R. S., Savage H. E., Rosen R. D. and Hersh E. M.

4. Continuous infusion chemotherapy and concomitant radiation therapy, (eds, Rosenthal C. J. and Rotman M.). *Plenum Press, New York, 1986, pp 19-25.* Authors: Benjamin R. S., Chawla S.P., Hortobagyi G. N., ewer M. S., Mackay B., Legha S. S., Carrasco C. H., and Wallace S.

5. Correlation of ejection fraction and biopsy grades in patients receiving adriamycin. *IN: Proceedings of the 14th International Congress of Chemotherapy, Kyoto, 1985 (ed, Ishigami J.), University of Tokyo, 1985, pp 251-252.* Authors: Ewer M. S., Chawla S.P., Carrasco C. H., Mackay B., Ali M. K., Haynie III T. P., and Benjamin R. S.

6. Adjuvant chemotherapy of primary malignant fibrous histiocytoma of bone: Prolongation of disease-free and overall survival. *IN: Adjuvant Therapy of Cancer IV (eds, Jones S. E. and Salmon S.*

Sant P. Chawla, M.D.

E.), Grune & Stratton, Florida, 1984, pp 621-629. Authors: Chawla S.P., Benjamin R. S., Abdul-Karim F. W., Ayala A. G., Papadopoulos N. E. J., Plager C., Romsdahl M., Jaffe N., Murray J. A.

7. Preoperative chemotherapy for osteosarcoma: A treatment approach facilitating limb- salvage wit major prognostic implications. *IN: Adjuvant Therapy of Cancer IV (eds, Jones S. E. And Salmon S. E.), Grune & Stratton, Florida, 1984, pp 601-610.* Authors: Benjamin R. S., Chawla S.P., Murray J. A., Carrasco C. H., Raymond A. K., Wallace S., Ayala A., Papadopoulos N. E. J., Plager C.

8. Mitoxantrone cardiotoxicity: Evaluation by nuclear angiography and endomyocardial biopsy. *IN: Pharmanual (ed, Smyth J. F.) Sieber & McIntyre, Inc., New Jersey, 1984, pp 49-56.* Authors: Benjamin R. S., Chawla S.P., Carrasco C. H., Mackay b., Haynie T. P., Yap H. V., Blumenschein G. R., Holmes F., Ali M. K., and Bodey G. P.

Abstracts

1. A randomized Bayesian phase 1 design combining an MPS-1 inhibitor with paclitaxel: A strategy to improve determination of the incremental toxicity of a novel compound over a known backbone therapy. *J Clin Oncol 36, 2018 (suppl; abstr 2537).* Authors: Florence Atrafi, Oliver Boix, Prabhu Rajagopalan, Anthony W. Tolcher, Patricia LoRusso, Joseph Paul Eder, Kamallesh Kumar Sankhala, Sant P. Chawla, Vivek Subbiah, Jennifer Robinson Diamond, Martin Gutierrez, Ron H.J. Mathijssen, Jian Mei, Jaap Verweij, Ingmar Bruns, Martijn P. Lolkema; Erasmus MC Cancer Institute, Rotterdam, Netherlands; These authors contributed equally. Bayer Pharma AG, Wuppertal, Germany; Bayer HealthCare Pharmaceuticals, Inc., Whippany, NJ; South Texas Accelerated Research Therapeutics, San Antonio, TX; Yale University School of Medicine–Yale Cancer Center, New Haven, CT; Yale University, New Haven, CT; Cedars-Sinai, Los Angeles, CA; Sarcoma Oncology Center, Santa Monica, CA; The University of Texas MD Anderson Cancer Center, Houston, TX; University of Colorado, Aurora, CO; Hackensack University Medical Center, Hackensack, NJ; Department of Medical Oncology, Erasmus MC Cancer Institute, Rotterdam, Netherlands; Bayer Pharmaceuticals, Whippany, NJ; Erasmus Univ Medcl Ctr, Rotterdam, Netherlands; Erasmus Medisch Centrum, Rotterdam, Netherlands

2. Efficacy and safety of lurbinectedin (PM1183) in Ewing sarcoma: Final results from a phase 2 study. *J Clin Oncol 36, 2018 (suppl; abstr 11519).* Authors: Vivek Subbiah, Kamallesh Kumar Sankhala, Ravin Ratan, Enrique Sanz Garcia, Valentina Boni, Thierry Gil, Victor Manuel Villalobos, Sant P Chawla, Pilar Lardelli, Mariano Siguero, Carmen Maria Kahatt, Arturo Soto-Matos, Stefano Ferrari; The University of Texas MD Anderson Cancer Center, Houston, TX; Sarcoma Oncology Center, Santa Monica, CA; Department of Sarcoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX; Hospital Vall D’Hebron, Barcelona, ES; START Madrid CIOCC Hospital Universitario Sanchinarro, Madrid, Spain; Institut Jules Bordet, Brussels, Belgium; University of Colorado, Denver, CO; PharmaMar, Madrid, Spain; Istituto Ortopedico Rizzoli, Bologna, Italy

3. Lack of cardiac toxicity in patients treated with aldoxrubicin with doxorubicin equivalent doses beyond 1000mg/m2. *J Clin Oncol 36, 2018 (suppl; abstr 11585).* Authors: Kamallesh Kumar Sankhala, Robin Lewis Jones, Victoria S. Chua, Katherine Kim, Shiva Sreenath Andrali, Doris V. Quon, Steven G.

Sant P. Chawla, M.D.

Wong, John H. Lee, Shahrooz Rabizadeh, Esha Sachdev, [Sant P. Chawla](#); Sarcoma Oncology Center, Santa Monica, CA; Royal Marsden Hospital, The Institute of Cancer Research, London, United Kingdom; Sarcoma Oncology Research Center, Santa Monica, CA; Hemophilia Treatmt Ctr, Los Angeles, CA; UCLA, Los Angeles, CA; Sanford Health, Sioux Falls, SD; NantOmics, LLC, Culver City, CA; Cedar-Sinai, Los Angeles, CA

4. TAPPAS: An adaptive enrichment phase 3 trial of TRC105 and pazopanib versus pazopanib alone in patients with advanced angiosarcoma. *J Clin Oncol* 36, 2018 (suppl; abstr TPS11590)

Authors: Vinod Ravi, Andrew Scott Brohl, [Sant P. Chawla](#), Steven Attia, Richard F. Riedel, David A. Liebner, Katherine Anne Thornton, Atrayee Basu Mallick, Cyrus R. Mehta, Lingyun Liu, Delia Alvarez, Charles P. Theuer, Steven Ian Robinson, Nicolas Penel, Silvia Stacchiotti, William D. Tap, Robin Lewis Jones, Robert G. Maki; Department of Sarcoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX; H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL; Sarcoma Oncology Center, Santa Monica, CA; Mayo Clinic, Jacksonville, FL; Duke University Medical Center, Durham, NC; The Ohio State University, Columbus, OH; Center for Bone and Soft Tissue Sarcoma, Brigham and Women's Hospital, Dana Farber Cancer Institute, Boston, MA; NSABP Foundation and Thomas Jefferson University Hospital, Philadelphia, PA; Cytel Inc, Cambridge, MA; TRACON Pharmaceuticals, Inc., San Diego, CA; Mayo Clinic, Rochester, MN; Oscar Lambret Cancer Center, Lille, France; Department of Cancer Medicine, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY; Royal Marsden Hospital, The Institute of Cancer Research, London, United Kingdom; Monter Cancer Center, Northwell Health and Cold Spring Harbor Laboratory, Lake Success, NY

5. Phase 2 results of selinexor in advanced de-differentiated (DDLs) liposarcoma (SEAL) study: A phase 2/3, randomized, double blind, placebo controlled cross-over study. *J Clin Oncol* 36, 2018 (suppl; abstr 11512).

Authors: Mrinal M. Gounder, Neeta Somaiah, Steven Attia, [Sant P. Chawla](#), Victor Manuel Villalobos, Bartosz Chmielowski, Melissa Amber Burgess, Gary K. Schwartz, Richard F. Riedel, Margaret von Mehren, Andrew J. Wagner, Edwin Choy, Shailendra Verma, Boyd Mudenda, Mara Sadanowicz, Jatin J. Shah, Lingling Li, Sharon Shacham, Michael G. Kauffman, Albiruni Ryan Abdul Razak; Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, NY; Department of Sarcoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX; Mayo Clinic, Jacksonville, FL; Sarcoma Oncology Center, Santa Monica, CA; University of Colorado, Denver, CO; University of California Los Angeles Medical Center, Los Angeles, CA; University of Pittsburgh Physicians, Pittsburgh, PA; Columbia University Medical Center, New York, NY; Duke University Medical Center, Durham, NC; Fox Chase Cancer Center, Philadelphia, PA; Dana-Farber Cancer Institute, Boston, MA; Massachusetts General Hospital, Boston, MA; Ottawa Hospital Cancer Centre, Ottawa, ON, Canada; Karyopharm Therapeutics, Newton, MA; Princess Margaret Cancer Centre, Toronto, ON, Canada

6. Phase 1/2 study of safety/efficacy using trabectedin, ipilimumab and nivolumab triple therapy as first line treatment of advanced soft tissue sarcoma. *J Clin Oncol* 36, 2018 (suppl; abstr TPS11591).

Authors: Erlinda Maria Gordon, Victoria S. Chua-Alcala, Katherine Kim, Shiva Sreenath Andrali, Marie Del Rosario, William W. Tseng, Seth Pollack, [Sant P. Chawla](#), Sarcoma Oncology Research Center; Sarcoma Oncology Center, Santa Monica, CA; Sarcoma Oncology Research Center, Santa Monica, CA;

Sant P. Chawla, M.D.

The University of Texas MD Anderson Cancer Center, Houston, TX; Fred Hutchinson Cancer Research Center, Seattle, WA

7. A phase 1b investigation of safety/efficacy of nivolumab and ABI-009 (*nab-rapamycin*) in advanced undifferentiated pleomorphic sarcoma (UPS), liposarcoma (LPS), chondrosarcoma (CS), osteosarcoma (OS) and Ewing sarcoma. *J Clin Oncol* 36, 2018 (suppl 5S; abstr TPS45). Authors: Erlinda Maria Gordon, Victoria S. Chua-Alcala, Katherine Kim, Doris M Quon, Sant P Chawla; Sarcoma Oncology Center, Santa Monica, CA; Cancer Center of Southern California, Santa Monica, CA

8. Cancer immunotherapy using trabectedin and nivolumab in advanced soft tissue sarcoma: A retrospective analysis. *J Clin Oncol* 36, 2018 (suppl 5S; abstr 40). Authors: Erlinda Maria Gordon, Kamalesh Kumar Sankhala, Nathan Stumpf, Joshua Ravicz, Suzan Arasheben, Bryan Leong, Grace Kang, Seth Kim, William W. Tseng, Sant P Chawla; Sarcoma Oncology Center, Santa Monica, CA; Department of Surgery, Section of Surgical Oncology, Keck School of Medicine, University of Southern California, Los Angeles, CA; Cancer Center of Southern California, Santa Monica, CA

9. Differential expression of human cyclin G1 (CCNG1) in cancer: A novel biomarker in development for CCNG1 inhibitor therapy. *J Clin Oncol* 36, 2018 (suppl; abstr e24315). Authors: Joshua Ravicz, Seiya Liu, Shiva Sreenath Andrali, Sandeep K. Reddy, Shankar Sellappan, Bryan Leong, Sant P. Chawla, Frederick L Hall, Erlinda Maria Gordon; Sarcoma Oncology Center, Santa Monica, CA; Sarcoma Oncology Research Center, Santa Monica, CA; NantHealth, Culver City, CA; NantOmics, LLC, Rockville, MD

10. Genomic and proteomic analysis of patient tumors for molecular target selection. *J Clin Oncol* 36, 2018 (suppl; abstr e23567). Authors: Shiva Sreenath Andrali, Erlinda Maria Gordon, Sandeep K. Reddy, Shankar Sellappan, John Chang, Esha Sachdev, Sant P. Chawla; Sarcoma Oncology Research Center, Santa Monica, CA; Sarcoma Oncology Center, Santa Monica, CA; NantOmics, LLC, Santa Cruz, CA; NantOmics, LLC, Rockville, MD; Cedar-Sinai, Los Angeles, CA

11. Clinical experience with combination chemo-/immunotherapy using trabectedin and nivolumab for advanced soft tissue sarcoma. *J Clin Oncol* 36, 2018 (suppl; abstr e23568). Authors: Sant P. Chawla, Kamalesh Kumar Sankhala, Joshua Ravicz, Grace Kang, Seiya Liu, Nathan Stumpf, Bryan Leong, Seth Kim, Susan Arasheben, William W. Tseng, Erlinda Maria Gordon; Sarcoma Oncology Center, Santa Monica, CA; Sarcoma Oncology Research Center, Santa Monica, CA; The University of Texas MD Anderson Cancer Center, Houston, TX

12. Detection of endoglin-expressing CTCs in patients enrolled in an adaptive enrichment phase 3 trial of TRC105 and pazopanib versus pazopanib alone in patients with advanced angiosarcoma (TAPPAS). *J Clin Oncol* 36, 2018 (suppl; abstr e23570). Authors: Vinod Ravi, Andrew Scott Brohl, Sant P. Chawla, Steven Attia, Richard F. Riedel, David A. Liebner, Katherine Anne Thornton, Atrayee Basu Mallick, Darren W. Davis, Mario Cervantes, Wen Liu, Keyi Zhu, Delia Alvarez, Charles P. Theuer, Steven Ian Robinson, Nicolas Penel, Silvia Stacchiotti, William D. Tap, Robin Lewis Jones, Robert G. Maki; Department of Sarcoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX; H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL; Sarcoma Oncology Center, Santa Monica, CA; Mayo Clinic, Jacksonville, FL; Duke University Medical Center, Durham, NC; The Ohio State University, Columbus, OH; Center for Bone and Soft Tissue Sarcoma, Brigham and Women's Hospital, Dana Farber Cancer Institute, Boston, MA; NSABP Foundation and Thomas Jefferson

Sant P. Chawla, M.D.

University Hospital, Philadelphia, PA; ApoCell, Inc., Houston, TX; TRACON Pharmaceuticals, Inc., San Diego, CA; Mayo Clinic, Rochester, MN; Oscar Lambret Cancer Center, Lille, France; Department of Cancer Medicine, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY; Royal Marsden Hospital, The Institute of Cancer Research, London, United Kingdom; Monter Cancer Center, Northwell Health and Cold Spring Harbor Laboratory, Lake Success, NY

13. Phase III study of aldoxorubicin vs investigators' choice as treatment for relapsed/refractory soft tissue sarcomas. Sant P. Chawla, Kristen N. Ganjoo, Scott Schuetze, Zsuzsanna Papai, Brian Andrew Van Tine, Edwin Choy, David A. Liebner, Mark Agulnik, Shanta Chawla, Scott Wieland, Daniel J. Levitt; ASCO 2017 annual meeting June 2, 2017. **J Clin Oncol 35, 2017 (suppl; abstr 11000).**

14. Administration of aldoxorubicin and 14 days continuous infusion of ifosfamide/mesna in metastatic or locally advanced sarcomas. Frederick C. Eilber, Kamallesh Kumar Sankhala, Sant P. Chawla, Victoria S. Chua-Alcala, Erlinda Maria Gordon, Doris Quon, Katherin Kim, Shanta Chawla, Nancy Wu, Scott Wieland, Daniel J. Levitt. **J Clin Oncol 35, 2017 (suppl; abstr 11051).**

15. Association of CMB305 or LV305-induced and baseline anti-NY-ESO-1 immunity with survival in recurrent cancer patients. Seth Pollack, Hailing Lu, Neeta Somaiah, Sant P. Chawla, John Charles Morris, Khanh Tu Do, Joseph W. Kim, Matthew Stephen Block, Marissa Vignali, Julie Rytlewski, Erik Yusko, Frank J. Hsu, Gerry C. Bohac, Sacha Gnjatich, and Jan Ter Meulen. **Journal of Clinical Oncology 35, 2017. (suppl; abstr 3090)**

16. A phase II trial of regorafenib (REGO) in patients (pts) with advanced Ewing sarcoma and related tumors (EWS) of soft tissue and bone: SARC024 trial results. Attia S, Bolejack V, Ganjoo KN, George S, Agulnik M, Rushing DA, Loggers ET, Livingston MB, Wright JA, Chawla SP, Okuno SH, Reinke DK, Riedel RF, Davis LE, Ryan CW, Maki RG. **J Clin Oncol 35, 2017.**

17. Immune response, safety, and survival impact from CMB305 in NY-ESO-1+ recurrent soft tissue sarcomas (STS). Neeta Somaiah, Sant P. Chawla, Matthew Stephen Block, John Charles Morris, Khanh Tu Do, Joseph W. Kim, Mihaela Druta, Kamallesh Kumar Sankhala, Patrick Hwu, Sacha Gnjatich, Hailing Lu, Richard T. Kenney, Gerry C. Bohac, Seth Pollack; **J Clin Oncol 35, 2017**

18. Phase 2 study of aldoxorubicin in relapsed glioblastoma. Morris D. Groves, Jana Portnow, Brian C. Boulmay, Sant P. Chawla, Hillary Dinh, Shanta Chawla, Scott Wieland, Daniel J. Levitt; Texas Oncology/The US Oncology Network, Austin, TX; City of Hope National Medical Center, Duarte, CA; Louisiana State Univ, New Orleans, LA; Director, Sarcoma Oncology Center, Santa Monica, CA; CytRx Corporation, Los Angeles, CA; CytRx Corp, Los Angeles, CA. **J Clin Oncol 34, 2016 (suppl; abstr 2027)**

19. Trabectedin for advanced soft-tissue sarcoma: A single-center experience of over 10 years. *J Clin Oncol 34, 2016 (suppl; abstr 11052).* Imran Syed, Madhuri Sudan, William Tseng, Prarthana Parthasarathy, William Esteves Mendanha, Neal Shiv Chawla, Rishi Nanda, Justin Daneshrad, Bryan Leong, Babak Aryanfar, Susan Arasheben, Katherine Kim, Erlinda Maria Gordon, Kamallesh Kumar Sankhala, Sant P. Chawla; Sarcoma Oncology Center, Santa Monica, CA; University of Southern California, Los Angeles, CA; Director, Sarcoma Oncology Center, Santa Monica, CA.

- 20. A phase 1/2 study of continuous infusion ifosfamide/mesna + aldoxorubicin in sarcoma patients.** Sant P. Chawla, Kamalesh Kumar Sankhala, Shanta Chawla, Victoria S. Chua, Erlinda Maria Gordon, Neal Shiv Chawla, Kelli Sung, Scott Wieland, Daniel J. Levitt. J Clin Oncol 34, 2016 (suppl; abstr e22547).
- 21. Long-term treatment of giant cell tumors of bone (GCTB) with denosumab: a two institutions 8-year experience.** N.S. Chawla, M. Sudan, I. Syed, Sant P. Chawla, S. Ferrari, P. Picci, E. Marchesi, M.P. Leopardi, K.K. Sankhala, P. Parthasarathy, W.E. Mendanha, A. Paioli, J. Daneshrad, E. Palmerini; J Clin Oncol 34, 2016. (suppl; abstr 11021)
- 22. Phase 1b study of aldoxorubicin + gemcitabine in metastatic solid tumors.** Kamalesh Kumar Sankhala, Shanta Chawla, Victoria S. Chua, Jasgit C. Sachdev, Erkut Hasan Borazanci, Kelli Sung, Monica M. Mita, Alain C. Mita, Brenda Laabs, Scott Wieland, Daniel J. Levitt, Sant P. Chawla. J Clin Oncol 34, 2016 (suppl; abstr 2523)
- 23. Subtype-specific activity in liposarcoma (LPS) patients (pts) from a phase 3, open-label, randomized study of eribulin (ERI) versus dacarbazine (DTIC) in pts with advanced LPS and leiomyosarcoma (LMS).** Sant P. Chawla, Patrick Schöffski, Giovanni Grignani, Jean-Yves Blay, Robert G. Maki, David R. D'Adamo, Matthew Guo, George D. Demetri;. J Clin Oncol 34, 2016 (suppl; abstr 11037)
- 24. The Selinexor in Advanced Liposarcoma (SEAL) study: A phase 2/3, multicenter, randomized, double blind study of selinexor versus placebo in patients with advanced, unresectable, dedifferentiated liposarcoma (DDLs).** Mrinal M. Gounder, Andrew J. Wagner, Neeta Somaiah, Richard F. Riedel, Gary K. Schwartz, Steven Attia, Albiruni R.A. Razak, Lee D. Cranmer, Scott H. Okuno, Mohammed M. Milhem, Cassandra Choe-Juliak, Sharon Shacham, Michael G. Kauffman, Sant P. Chawla. J Clin Oncol 34, 2016 (suppl; abstr TPS11072)
- 25. Study of the safety and efficacy of the combination of gemcitabine and docetaxel with ontuxizumab (MORAb-004) in metastatic soft tissue sarcoma.** J Clin Oncol 33, 2015 (suppl; abstr TPS10577) Sant P. Chawla, Patrick Schoffski, Jean-Yves Blay, Robin Lewis Jones, Hans Gelderblom, Steven Attia, Bartosz Chmielowski, Brian Andrew Van Tine, Jonathan C. Trent, Shreyaskumar Patel, Andrew J. Wagner, James Kert Viele, Rashmi Chugh, Axel Le Cesne, Gabriel Tinoco, Kamalesh Kumar Sankhala, Julianne Falcone, Charles Schweizer, Susan Weil, Robert G. Maki.
- 26. Longer term cardiac safety of aldoxorubicin.** J Clin Oncol 33, 2015 (suppl;abstr 10546).Sant P. Chawla, Kamalesh Sankhala, Scott Wieland, Daniel J. Levitt; Sarcoma Oncology Center, Santa Monica, CA; CytRx Corporation, Los Angeles, CA .
- 27. Randomized, open-label, multicenter, phase 3 study of eribulin versus dacarbazine in patients with leiomyosarcoma and adipocytic sarcoma: subgroups analyses.** CTOS Oral Presentation 05 Nov. 2015. Sant Chawla MD, Shreyaskumar Patel MD, Edwin Choy MD PhD, Viktor Gruenwald⁴, Peter Hohenberger MD, David R D'Adamo MD PhD⁶, Ren Chen⁶, Giovanni Grignani MD, Robin L Jones⁸, Patrick Schöffski MD MPH, Robert G Maki MD PhD
- 28. Efficacy and Safety of Trabectedin or Dacabazine for Treatment of Patients with Advanced Leiomyosarcoma or Liposarcoma after Prior Chemotherapy.** European Cancer Congress, September 2015, Vienna, Austria. George D. Demetri, Shreyaskumar R. Patel, Samuel Thomas, Michael Livingston, Samir Undevia, Gary Richardson, Arun Singh, Rahul Seth, Charles Forscher, Iona Hinshaw, Atif Hussein, Gina

Sant P. Chawla, M.D.

D'Amato, Sant Chawla, Nushmia Z Khokhar, Youn Choi Park, Roland E. Knoblauch Trilok V. Parekh, Robert G. Maki, Margaret von Mehren.

29. Randomized, open-label, multicenter, phase III study of eribulin versus dacarbazine in patients (pts) with leiomyosarcoma (LMS) and adipocytic sarcoma (ADI). *J Clin Oncol* 33, 2015 (suppl; abstr LBA10502) . Patrick Schöffski, Robert G. Maki, Antoine Italiano, Hans Gelderblom, Giovanni Grignani, Veridiana Pires De Camargo, Sebastian Bauer, Sun Young Rha, Sant P. Chawla, Jean-Yves Blay, Peter Hohenberger, David R. D'Adamo, Benjamin Wang, Bartosz Chmielowski, Axel Le Cesne, George D. Demetri, Shreyaskumar Patel

30. Molecularly-guided therapeutic options beyond tyrosine kinase inhibitors (TKIs) for gastrointestinal stromal tumors (GIST). *J Clin Oncol* 33, 2015 (suppl 3; abstr 58). Authors: Rebecca Feldman, Zoran Gatalica, Sandeep K. Reddy, Sant P. Chawla, Kamalesh Kumar Sankhala; Caris Life Sciences, Phoenix, AZ; Caris Life Sciences, Irving, TX; Sarcoma Oncology Center, Santa Monica, CA

31. Phase 2 study of gemcitabine, docetaxel, and doxorubicin in patients with advanced, unresectable, and/or metastatic sarcoma who have failed prior therapies. *J Clin Oncol* 33, 2015 (suppl; abstr 10573) Authors: Andrew Eugene Hendifar, Neal S Chawla, Kamalesh Kumar Sankhala, Xiao Zhang, Doris V. Quon, Victoria S Chua, Lita Fernandez, William E. Mendanha, Sant P. Chawla; Cedars-Sinai Medical Center, Los Angeles, CA; Sarcoma Oncology Center, Santa Monica, CA; Hemophilia Treatmt Ctr, Los Angeles, CA

32. Genomic mutation profiling (GMP) and clinical outcome of patients treated with buparlisib (PI3K inhibitor) in the “Signature” program. *J Clin Oncol* 33, 2015 (suppl; abstr 2516) Authors: Sarina Anne Piha-Paul, James A. Knost, Fadi S. Braiteh, J. Thaddeus Beck, Daniel Lewis Spitz, Steven W. Papish, Beth A. Hellerstedt, Petros Nikolidakos, Matthew Hiram Taylor, Sant P. Chawla, Lee Steven Schwartzberg, David A. Smith, Sebastian Szpakowski, Lening Zhang, Theresa White, Claudia Lebedinsky; Department of Investigational Cancer Therapeutics (Phase 1 Program), The University of Texas MD Anderson Cancer Center, Houston, TX; Illinois Cancer Care, Peoria, IL; Comprehensive Cancer Centers of Nevada, University of Nevada School of Medicine, Las Vegas, NV; Highlands Oncology Group, Fayetteville, AR; Palm Beach Cancer Inst, West Palm Beach, FL; Carol G Simon Cancer Ctr, Morristown, NJ; US Oncology Research, LLC, McKesson Specialty Health, and Texas Oncology, Central Austin Cancer Center, Austin, TX; Northeast Georgia Cancer Care, Athens, GA; Oregon Health and Science University, Portland, OR; Sarcoma Oncology Center, Santa Monica, CA; University of Tennessee Health Science Center, Memphis, TN; Compass Onc, Vancouver, WA; Novartis Institutes for BioMedical Research, East Hanover, NJ; Novartis Pharmaceuticals, East Hanover, NJ; Novartis Pharmaceuticals Corporation, East Hanover, NJ

33. Sustained response of complex giant cell tumors with denosumab: Single center 8-year experience.

J Clin Oncol 33, 2015 (suppl; abstr 10528) Authors: Neal Shiv Chawla, Susan V. Bukata, Kamallesh Kumar Sankhala, William E. Mendanha, Vivek Narasimhan, Lawrence Menendez, Nicholas Bernthal, Earl W. Brien, Victoria S. Chua, Sant P. Chawla; Sarcoma Oncology Center, Santa Monica, CA; UCLA Orthopaedics, Santa Monica, CA; University of Southern California Norris Comprehensive Cancer Center, Los Angeles, CA; UCLA Orthopaedics, Los Angeles, CA; Cedars-Sinai Medical Center, Samuel Oschin Comprehensive Cancer Center Institute, Los Angeles, CA

34. A multicenter phase II basket clinical trial of lurbinectedin (PM01183) in selected advanced solid tumors.

J Clin Oncol 33, 2015 (suppl; abstr TPS2604) Authors: Mariano Provencio Pulla, Josep Taberner, Victor Moreno, Jose Manuel Trigo Perez, Rafael Lopez, Rebecca Kristeleit, Ahmad Awada, Alexandra Leary, Jerome Alexandre, Jean-Pierre Delord, Stefano Ferrari, Armando Santoro, Emilio Bajetta, Vivek Subbiah, Steven Weitman, Victor Manuel Villalobos, Eric Raymond, Anna Sundlov, Pilar Lardelli, Sant P. Chawla; Hospital Puerta de Hierro, Madrid, Spain; Vall d'Hebron University Hospital, Barcelona, Spain; Fundación Jiménez Díaz, Madrid, Spain; Hospital Universitario Virgen de la Victoria, Malaga, Spain; Hospital Clinico Universitario de Santiago de Compostela, Santiago De Compostela, Spain; University College London Hospitals, London, United Kingdom; Jules Bordet Institute, Bruxelles, Belgium; Institut de Cancérologie Gustave Roussy, Villejuif, France; Medical Oncology, Paris Descartes University, Cochin - Port Royal Hospital, AP-HP, Paris, France; Institut Claudius Regaud, Department of Medicine, Toulouse, France; Istituto Ortopedico Rizzoli, Bologna, Italy; Istituto Clinico Humanitas, Rozzano Milano, MI, Italy; Istituto di Oncologia, Policlinico di Monza, Monza, Italy; Department of Investigational Cancer Therapeutics (Phase 1 Program), The University of Texas MD Anderson Cancer Center, Houston, TX; Cancer Therapy & Research Center's, San Antonio, TX; University of Colorado Cancer Center, Aurora, CO; CHUV, Lausanne, Switzerland; University Hospital of Skåne, Malmö, Sweden; PharmaMar, Madrid, Spain; Sarcoma Oncology Center, Santa Monica, CA

30. Randomized phase 2b trial comparing first-line treatment with aldoxorubicin versus doxorubicin in patients with advanced soft tissue sarcomas.

ASCO Abstract 2014, Abstract # 10502. Authors: Sant P. Chawla, Zsuzsanna Papai, Kamallesh Sankhala, Leonid Vasylyev, Guzel Mukhametsina, Mamed Aliev, Kenneth Khamly, Scott Wieland, Daniel J. Levitt; Sarcoma Oncology Center, Santa Monica, CA; Oncology Department, State Health Center, Budapest, Hungary; CTIC Institute for Drug development, San Antonio, TX; Institute of Medical Radiology, Kharkiv, Ukraine; State Healthcare Institute Republican Clinical Oncological Center of the Ministry of Health of the Republic of Tatarstan, Kazan, Russia; Blokhin Cancer Research Center, Moscow, Russia; Epworth Healthcare and Clinical Trials Research Centre, Richmond, Australia; CytRx Corporation, Los Angeles, CA.

31. Pazopanib in uterine sarcoma (UtS): Review of two European Organisation for Research and Treatment of Cancer (EORTC) and GSK clinical trials 62043 and 62072 on pazopanib for soft tissue sarcoma (STS). *ASCO Abstract 2014, Abstract No. 10579.* Authors: Isabelle Laure Ray-Coquard, Stefan Sleijfer, Saskia Litière, Jean-Yves Blay, Axel Le Cesne, Zsuzsanna Papai, Ian Robert Judson, Patrick Schoffski, Sant P. Chawla, Thierry Gil, Sophie Piperno-Neumann, Sandrine Marraud, Rachel Hodge, Winette T.A. Van Der Graaf; Centre Léon Bérard, Lyon, France; Erasmus MC Cancer Institute,

Sant P. Chawla, M.D.

Department of Medical Oncology and Cancer Genomics Netherlands, Rotterdam, Netherlands; European Organisation for Research and Treatment of Cancer, Brussels, Belgium; Institut Gustave Roussy, Villejuif, France; Oncology Department, State Health Center, Budapest, Hungary; The Royal Marsden NHS Foundation Trust, London, United Kingdom; Laboratory of Experimental Oncology and Department of General Medical Oncology, KU Leuven and University Hospitals, Leuven, Belgium; Sarcoma Oncology Center, Santa Monica, CA; Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium; Institut Curie, Paris, France; GlaxoSmithKline Oncology, Uxbridge, United Kingdom; Department of Medical Oncology, Radboud University Medical Center, Nijmegen, Netherlands.

32. Response to treatment with denosumab in patients with giant cell tumor of bone (GCTB): FDG PET results from two phase 2 trials. *ASCO Abstract 2014, Abstract No. 10505.* Authors: Keith M. Skubitz, David Morgan Thomas, [Sant P. Chawla](#), Arthur P. Staddon, Jacob Engellau, Amy Feng, Bruce A. Bach; University of Minnesota, Minneapolis, MN; Peter MacCallum Cancer Centre, Melbourne, Australia; Sarcoma Oncology Center, Santa Monica, CA; Pennsylvania Oncology Hematology Associates, Philadelphia, PA; Skåne University Hospital, Lund, Sweden; Amgen Inc., Thousand Oaks, CA; Amgen, Inc., Thousand Oaks, CA.

33. Low-dose gemcitabine doxorubicin and docetaxel combination in patients with advanced/unresectable/metastatic sarcoma who failed prior chemotherapy: Updated analysis. *ASCO Abstract 2014, Abstract No. 10599.* Authors: Vivek Narasimhan, James Hu, Kamallesh Kumar Sankhala, Doris V. Quon, Lawrence Menendez, Lita Fernandez, Victoria S Chua, [Sant P. Chawla](#); Sarcoma Oncology Center, Santa Monica, CA; USC Norris Comprehensive Cancer Center, Los Angeles, CA.

34. 14-day continuous infusion ifosfamide in advanced refractory sarcomas. *ASCO Abstract 2014, Abstract No. 10596.* Authors: Arun S. Singh, Kamallesh Kumar Sankhala, Arnob Mukherjee, Vivek Narasimha, Bartosz Chmielowski, Doris V. Quon, Vicky Chua, [Sant P. Chawla](#); University of California Los Angeles Medical Center, Santa Monica, CA; Sarcoma Oncology Center, Santa Monica, CA; School of Medicine/Translational Oncology Research Laboratory, University of California, Los Angeles, Los Angeles, CA.

35. Efficacy and safety of denosumab in giant cell tumor of bone. *GCTB encore submission to ISOLS.* Authors: Robert Grimer, Jean-Yves Blay, [Sant P. Chawla](#), Edwin Choy, Stefano Ferrari, Peter Reichart, Piotr Rutkowski, David Thomas, Yi Qian, Ira Jacobs.

36. Phase 1b study of RG7112 with doxorubicin (D) in advanced soft tissue sarcoma.(ASTS) ASCO 2013. Authors: [SP Chawla](#), JY Blay, A Italiano, M Gutierrez, A Le Cesne, CA Gomez-Roca, L Gouw, M von Mehren, AJ Wagner, RG Maki, BX Higgins, S Middleton, G Nichols, D Geho, S Blotner, J Zhi, LC Chen.

37. A randomized, double-blind, placebo (Pbo)-controlled phase III study of ombrabulin plus cisplatin in patients (pts) with advanced-stage soft-tissue sarcoma after failure of anthracycline and ifosfamide chemotherapies. *J Clin Oncol 31, 2013 (suppl; abstr 10506)* Authors: Zsuzsanna Papai, Anthony W. Tolcher, Antoine Italiano, Didier Cupissol, Antonio Lopez-Pousa, Sant P. Chawla, Emmanuelle Bompas, Nicolas Penel, Nicolas Isambert, Arthur P. Staddon, Antoine Thyss, Armando Santoro, Fabio A. Franke, Patrick Cohen, Solenn Le-Guenneq, George D. Demetri, Jean-Yves Blay; Állami Egészségügyi Központ, Budapest, Hungary; South Texas Accelerated Research Therapeutics (START), San Antonio, TX; Institut Bergonié, Bordeaux, France; Centre Val d'Aurelle, Montpellier, France; Hospital de la Santa Creu i Sant Pau, Barcelona, Spain; St. John's Hospital, Santa Monica, CA; Centre René Gauducheau, Nantes, France; Centre Oscar Lambret, Lille, France; Centre Georges François Leclerc, Dijon, France; Pennsylvania Oncology Hematology Associates, Philadelphia, PA; Centre Antoine Lacassagne, Nice, France; Istituto Clinico Humanitas IRCCS, Milano, Italy; CACON-Hospital de Caridade de Ijuí, Ijuí, Brazil; Sanofi, Vitry-sur-Seine, France; Ludwig Center at Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA; Centre Léon Bérard, Lyon, France

38. Results of the randomized phase III trial of trabectedin (T) versus doxorubicin-based chemotherapy (DXCT) as first-line therapy in patients (pts) with translocation-related sarcoma (TRS). *J Clin Oncol 31, 2013 (suppl; abstr 10517)* Authors: Andrew Eugene Hendifar, Sant P. Chawla, Michael Gordon Leahy, Antoine Italiano, Shreyaskumar Patel, Armando Santoro, Arthur P. Staddon, Nicolas Penel, Sophie Piperno-Neumann, George D. Demetri, Larry Hayward, Jeff White, Launce G. Gouw, Bernardo De Miguel, Pilar Lardelli, Arturo Soto, Antonio Nieto, Jean-Yves Blay; Sarcoma Oncology Center, Santa Monica, CA; The Christie Hospital NHS Foundation Trust, Manchester, United Kingdom; Institut Bergonié, Bordeaux, France; The University of Texas MD Anderson Cancer Center, Houston, TX; Humanitas Cancer Center, Rozzano, Italy; Pennsylvania Hospital, Philadelphia, PA; Centre Oscar Lambert, Lille, France; Institut Curie, Paris, France; Dana-Farber Cancer Institute/Harvard Medical School, Boston, MA; Edinburgh Cancer Research UK Center, Western General Hospital, Edinburgh, United Kingdom; The Beatson West of Scotland Cancer Centre, Glasgow, United Kingdom; Huntsman Cancer Institute, University of Utah, Salt Lake City, UT; PharmaMar, Madrid, Spain; University Claude Bernard Lyon I, Centre Léon Bérard, Lyon, France

39. A phase II trial of novel anthracycline amrubicin in advanced soft tissue sarcoma. *J Clin Oncol 31, 2013 (suppl; abstr 10587)* Authors: Launce Gouw, R Lor Randall, Kevin Jones, Sant P. Chawla, Sunil Sharma; Huntsman Cancer Institute, Salt Lake City, UT; Sarcoma Oncology Center, Santa Monica, CA

40. Phase Ib trial of combining aldoxorubicin plus doxorubicin. *J Clin Oncol 31, 2013 (suppl; abstr 2550)* Authors: Kamalesh Kumar Sankhala, Sant P. Chawla, Victoria S Chua, Doris Quon, Allison Bonk, Vivek Narasimhan, Monish Sodhi, Nina Krishna, Hillary Dinh, Scott Wieland, Daniel Levitt; University of Texas Health Science Center at San Antonio, San Antonio, TX; Sarcoma Oncology Center, Santa Monica, CA; CytRx Corporation, Los Angeles, CA

41. A randomized, double-blinded, placebo-controlled, multi-institutional, cross-over, phase II.5 study of saracatinib (AZD0530), a selective src kinase inhibitor, in patients with recurrent osteosarcoma localized to the lung. *J Clin Oncol 31, 2013 (suppl; abstr TPS10591)* Authors: Kristin Baird, Denise K. Reinke, Joseph Gerald Pressey, Leo Mascarenhas, Noah Federman, Neyssa Marina, Sant P. Chawla, Joanne Pignes Lagmay, John M. Goldberg, Mohammed M. Milhem, David Mark Loeb, James E. Butrynski, Katherine A. Janeway, Brian Turpin, Arthur P. Staddon, Sheri L. Spunt, Eve T. Rodler, Scott Schuetze, Scott H. Okuno, Lee J. Helman; National Cancer Institute, Bethesda, MD; Sarcoma Alliance for Research through Collaboration, Ann Arbor, MI; University of Alabama at Birmingham, Birmingham, AL; Children's Hospital Los Angeles, Los Angeles, CA; Department of Pediatrics, University of California, Los Angeles, Los Angeles, CA; Stanford University, School of Medicine, Palo Alto, CA; Sarcoma Oncology Center, Santa Monica, CA; Nationwide Children's Hospital, Gainesville, FL; University of Miami, Miller School of Medicine, Miami, FL; University of Iowa Hospital and Clinics, Iowa City, IA; The Johns Hopkins University, Baltimore, MD; Dana-Farber Cancer Institute, Boston, MA; Cincinnati Children's Hosp Med Ctr, Cincinnati, OH; University of Pennsylvania, Philadelphia, PA; St. Jude Children's Research Hospital, Memphis, TN; Seattle Cancer Care Alliance, Seattle, WA; University of Michigan, Ann Arbor, MI; Mayo Clinic, Rochester, MN; Center for Cancer Research, National Cancer Institute, Bethesda, MD

Randomized phase III, multicenter, open-label study comparing TH-302 in combination with doxorubicin versus doxorubicin alone in subjects with locally advanced unresectable or metastatic soft tissue sarcoma. *J Clin Oncol 30, 2012 (suppl; abstr TPS10100)* Authors: Sant P. Chawla, Denise K. Reinke, Sam Saks, Stew Kroll, William D. Tap; Sarcoma Oncology Center, Santa Monica, CA; University of Michigan, Ann Arbor, MI; Threshold Pharmaceuticals, Redwood City, CA; Memorial Sloan-Kettering Cancer Center, New York, NY

42. Seguridad y eficacia de denosumab en el tumor de células gigantes de hueso (TCG): análisis interino de un ensayo de fase 2. *Submitted 2o Simposio Nacional de la SEOM, Madrid 24 – 26 Octubre 2012.* Authors: J. Martin Broto (1), J. Y. Blay (2), S. P. Chawla (3), E. Choy (4), M. Dominkus (5), J. Engellau (6), R. Grimer (7), R. M. Henshaw (8), Y. Qian (9), I. A. Jacobs (9).

43. Growth modulation index (GMI) as a metric of clinical benefit assessment among advanced soft tissue sarcoma (ASTS) patients receiving trabectedin as salvage therapy. *Submitted to 2012 ASCO Annual Meeting, June 1-5, 2012.* Authors: Nicolas Penel, George D. Demetri, Jean-Yves Blay, Sophie Cousin, Robert G. Maki, Sant P. Chawla, Ian Robert Judson, Margaret von Mehren, Patrick Schoffski, Jaap Verweij, Paolo Giovanni Casali, Sjoerd Rodenhuis, Javier Gomez, Antonio Nieto, Patrik Zintl, Maria Jose Pontes Valero, Alexia Cassar, Axel Le Cesne; Centre Oscar Lambret, Lille, France; Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA; University Claude Bernard Lyon I, Centre Léon Bérard, Lyon, France; Mount Sinai School of Medicine, New York, NY; Sarcoma Oncology Center, Santa Monica, CA; The Royal Marsden NHS Foundation Trust, London, United

Sant P. Chawla, M.D.

Kingdom; Fox Chase Cancer Center, Philadelphia, PA; Department of General Medical Oncology, Leuven Cancer Institute, Catholic University of Leuven, Leuven, Belgium; Erasmus University Medical Center, Rotterdam, Netherlands; Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy; Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, Amsterdam.

44. Phase I study of BPM 31510 in advanced solid tumors: Updated analysis of a novel treatment with promising activity. *J Clin Oncol* 30, 2012 (suppl; abstr 3015); ASCO 2012. Authors: Andrew Eugene Hendifar, [Sant P. Chawla](#), Doris Quon, Victoria S Chua, Lita Fernandez, Sandeep Nagre, Marita Okunnu, Bartosz Chmielowski, Arun S. Singh, Slava Akmaev, David Chatman, John McCook, Shen Luan, Rangaprasad Sarangarajan, Paul Y. Song, Niven R Narain.

45. Phase Ib/II study of INNO-206 (EMCH-doxorubicin) in patients with soft tissue sarcoma. *J Clin Oncol* 30, 2012 (suppl; abstr 10036); ASCO 2012. Authors: [Sant P. Chawla](#), Victoria S Chua, Andrew Hendifar, Doris Quon, Sandeep Nagre, Kristen N. Ganjoo, Kamalesh Sankhala, Scott Wieland, Daniel Levitt.

46. Global differences in chemotherapeutic regimens of soft tissue sarcoma (STS): Results of PALETTE, an EORTC 62072/GSK VEG110727 global network phase III trial of pazopanib versus placebo. *J Clin Oncol* 30, 2012 (suppl; abstr 10067) Authors: Sandrine Marreaud, Winette T.A. Van der Graaf, Jean-Yves Blay, [Sant P. Chawla](#), Jeeyun Lee, Binh Bui Nguyen, Paolo Giovanni Casali, Massimo Aglietta, Arthur P. Staddon, Yasuo Beppu, Axel Le Cesne, Hans Gelderblom, Ian Robert Judson, Nobuhito Araki, Monia Ouali, Mohamedraza Dewji, Alex Powell, George D. Demetri, Peter Hohenberger; EORTC Headquarters, Brussels, Belgium; Radboud University Medical Centre, Nijmegen, Netherlands; Centre Léon Bérard, Lyon, France; Sarcoma Oncology Center, Santa Monica, CA; Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea; Institut Bergonie, Bordeaux, France; Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy; Institute for Cancer Research and Treatment, Candiolo, Italy; University of Pennsylvania, Philadelphia, PA; National Cancer Center Hospital, Tokyo, Japan; Institut Gustave Roussy, Villejuif, France; Department of Clinical Oncology, Leiden University Medical Center, Leiden, Netherlands; Sarcoma Unit, The Royal Marsden Hospital NHS Foundation Trust, London, United Kingdom; Osaka Medical Center, Osaka, Japan; European Organisation for Research and Treatment of Cancer Headquarters, Brussels, Belgium; GlaxoSmithKline R&D, Greenford, United Kingdom; Hollywood Medical Center, Nedlands, Australia; Dana-Farber Cancer Institute/Harvard Medical School, Boston, MA; Department of Surgery, Mannheim University Medical Center, Mannheim, Germany

47. Randomized multicenter phase III trial of trabectedin (T) versus doxorubicin-based chemotherapy as first-line therapy in patients with translocation-related sarcoma (TRS). *J Clin Oncol* 30, 2012 (suppl; abstr TPS10101) Authors: Jean-Yves Blay, Michael Gordon Leahy, Binh Bui Nguyen, Shreyaskumar Patel, Armando Santoro, Peter Hohenberger, George D. Demetri, Pilar Lardelli, Iratxe Perez, Sant P. Chawla; Centre Léon Bérard, Lyon, France; The Christie NHS Foundation Trust, Manchester, United Kingdom; Institut Bergonie, Bordeaux, France; University of Texas M. D. Anderson Cancer Center, Houston, TX; Humanitas Cancer Center, Istituto Clinico Humanitas IRCCS, Rozzano, Italy; Universitätsklinikum Mannheim, Mannheim, Germany; Dana-Farber Cancer Institute/Harvard Medical School, Boston, MA; PharmaMar, Madrid, Spain; Sarcoma Oncology Center, Santa Monica, CA

48. Denosumab Induces Tumor Reduction and Bone Formation in Patients with Giant Cell Tumor of Bone. *Submitted to Clinical Cancer Research February, 2012.* Authors: Daniel G. Branstetter, Scott D. Nelson, J. Carlos Manivel, Jean-Yves Blay, Sant Chawla, David M. Thomas, Susie Jun, Ira Jacobs.

49. Evaluating the Safety and Efficacy of Denosumab in Patients with Giant Cell Tumor of Bone (GCTB): Second Interim analysis from A Phase 2 Study. *Submitted to 2011 CIBD Conference Nov 30-Dec 3, 2011.* Authors: Chawla S. et al.

50. Denosumab Safety and Efficacy in Giant Cell Tumor of Bone (GCTB): Interim Results From A Phase 2 Study. *2011 ASCO Annual Meeting, June 3-7, 2011. Abstract #82649.* Authors: Chawla S. et al.

51. The GeneVieve Protocol. *2011 ASCO Annual Meeting, June 3-7, 2011. Abstract #49252.* Authors: Ignacio J.G., Chawla S.P. et al: A Phase I/II Study of Intravenous Rixin-G and Riximmune-C for Cancer Immunotherapy.

52. A Randomized Multicenter Phase III Trial of Trabectedin (T) vs Doxorubicin-Based Chemotherapy (DXCT) as First-Line Therapy (Rx) in Patients (pts) with Translocation Related Sarcoma (TRS). *Submitted to 2011 ASCO Annual Meeting, June 3-7, 2011.* Authors: Chawla S.P. et al.

53. A Phase 3, randomized, placebo-control trial evaluating the mTOR inhibitor ridaforolimus as maintenance therapy in advanced sarcoma patients who achieve clinical benefit from chemotherapy (SUCCEED trial). *Submitted to 2011 ASCO Annual Meeting, June 3-7, 2011.* Authors: Chawla S.P. et al.

54. PALETTE: A randomized double blind phase III trial of pazopanib versus placebo in patients with soft tissue sarcoma (STS) whose disease has progressed during or following prior therapy. An EORTC STBSG global network study (EORTC 62072). *Submitted to 2011 ASCO Annual Meeting, June 3-7, 2011.* Authors: Van der Graaf WTA, Blay JY, Chawla S. et al.

55. A Phase 2 Dose Expansion of TH-302 in Combination with Doxorubicin in Soft Tissue Sarcoma. *Submitted to 2011 ASCO Annual Meeting, June 3-7, 2011.* Authors: Ganjoo K.N., Cranmer L., Adkins D., Reed D.R., Okuno S.H., Butrynski J.E., Rushing D., Lorente G.A., Kroll S., Chawla S.P.

56. A Phase I study to assess pharmacokinetics, QT/QTc effect, and safety of amrubicin in patients with advanced solid tumors. *Submitted to 2011 ASCO Annual Meeting, June 3-7, 2011.* Authors: Sharma S., Chawla S., et al.

57. A Phase II Study of VEGF-antisense compound (VEGF-AS, Veglin) with Pemetrexed and Cisplatin in Patients with Malignant Mesothelioma. *Submitted to 2011 ASCO Annual Meeting, June 3-7, 2011.* Authors: Chawla, S.P., et al.

58. A Phase II Study of VEGF-AS Veglin With Pemetrexed and Cisplatin, CAV Regimen, in the Treatment of Patients With Malignant Mesothelioma. *2010 Chicago Multidisciplinary Symposium in Thoracic Oncology, December 9-11, 2010. Abstract #161.* Authors: Chawla S.P., Lazaro C.B., Hendifar A., Gupta R.R., Rana R., Nadadur R. Chua V.S.

59. A Phase II Study of Low Dose TAG (Taxotere, Adriamycin, Gemcitabine) as Salvage Therapy for Soft Tissue Sarcoma. *CTOS 16th Annual Meeting, Nov. 11-13, 2010. Abstract #896893.* Authors:

Sant P. Chawla, M.D.

Ganjoo K.N., Jahan T.M., Lazaro C.B., Chen A.L., Gupta R.R., Jain R.K., Chua V.S., Cranmer L.D., Chawla S.P.

60. A Phase 1/2 Study of TH-302 in Combination with Doxorubicin in Soft Tissue Sarcoma. *CTOS 16th Annual Meeting, Nov. 11-13, 2010. Abstract #900676.* Authors: Chawla, S.P., et al.

61. Efficacy and Safety of Conatumumab Plus AMG 479 in Patients (PTS) with Advanced Sarcoma. *CTOS 16th Annual Meeting, Nov. 11-13, 2010. Abstract #890126.* Authors : Chawla S.P., et al.

62. Yondelis® (Trabectedin) hepatic safety profile as single-agent in soft tissue sarcoma (STS): Pooled analysis of phase II trials. *CTOS 16th Annual Meeting, Nov. 11-13, 2010. Abstract #876470.* Authors: Demetri G.D., Le Cesne A., Yovine A., Maki R., Chawla S.P., et al.

63. A Phase II trial of R1507, a monoclonal antibody to the Insulin-Like Growth Factor-1 receptor (IGF1R) in patients with recurrent or refractory bone and soft tissue sarcomas excluding ESFT. *CTOS 16th Annual Meeting, Nov. 11-13, 2010. Abstract #900715.* Authors: Pappo A., Patel S., Crowley J., Reinke D., Brownstein C., Chawla S., et al.

64. Advanced Phase I/II Evaluation of Tumor-Targeted Gene Delivery: Intravenous Rexin-G as Stand Alone Therapy for Chemotherapy-resistant Bone and Soft Tissue Sarcoma. *CTOS 16th Annual Meeting, Nov. 11-13, 2010. Abstract #890419.* Authors: Ganjoo K.N., Chawla S.P., et al.

65. Denosumab in Giant Cell Tumor of Bone: Interim Results from a Phase 2 Study. *CTOS 16th Annual Meeting, Nov. 11-13, 2010. Abstract #900789.* Authors: Chawla S.P., et al.

66. Denosumab decreases proliferation in Giant Cell Tumor of Bone (GCTB). *10th International Conference on Cancer-Induced Bone Disease. Sept 22 – Sept 25, 2010.* Authors: Roudier M., Blay J.Y., Chawla S., et al.

67. Advanced Phase I/II Evaluation of Tumor-Targeted Gene Delivery: Intravenous Infusions of Retrovector Encoding Mutant Anti-Cyclin G1 as Stand-alone Therapy for Chemotherapy-Resistant Bone and Soft Tissue Sarcoma. *2010 ASCO Abstract. June 4 - June 8, 2010. Abstract #: 10010.* Authors: Ganjoo K.N., Chawla S.P., et al.

68. A phase I/II study of intravenous rexin-g and reximmune-c for cancer immunotherapy: The GeneVieve protocol. *2010 ASCO Abstract. June 4 - June 8, 2010. Abstract #: 49252.* Authors: Ignacio J.G., Chawla S.P., et al.

69. An open-label, dose-ranging study to assess the safety, efficacy, and pharmacokinetics of eltrombopag in treating thrombocytopenia in patients with advanced sarcomas receiving doxorubicin and ifosfamide; *2010 ASCO Abstract. June 4 - June 8, 2010.* Authors: Authors: Chawla S.P., Staddon A.P., Messam C., Graham A.M., Mostafa Kamel Y.M.

70. Phase I evaluation of the safety of conatumumab (AMG 655) in combination with AMG 479 in patients (pts) with advanced, refractory solid tumors. *2010 ASCO Abstract. June 4 - June 8, 2010.* Authors: Chawla S.P., Taberner J., Kindler H.L., Chiorean E.G., LoRusso P., Hsu M., Haddad V., Bach B.A., Baselga J.

- 71. TH-302, a novel tumor-selective hypoxia-activated prodrug (HAP): Phase 1 safety and activity as monotherapy and in combination with gemcitabine, docetaxel, pemetrexed and doxorubicin.** *2010 New Zealand Society for Oncology Annual Conference Abstract.* Authors: Langmuir V, Kroll S, Weiss G, Infante J, Borad M, Chiorean E G, Mita A, Ganjoo K, Chawla S, et al.
- 72. Trabectedin (Tr) in the treatment of advanced uterine leiomyosarcomas (U-LMS): results of a pooled analysis of five single-agent phase II studies.** *2010 ASCO Abstract. June 4 - June 8, 2010.* Authors: Judson I, Blay J Y, Chawla S, Radford J, Le Cesne A, Verweij J, VonMehren M, Demetri G.
- 73. Targeting tumor hypoxia with TH-302: Phase I results with monotherapy and combination with chemotherapy.** Authors: Chawla SP, et al.
- 74. Evaluation of the Safety and Efficacy of "Pathotropic" Nanoparticles Bearing a Dominant-Negative Cyclin G1 Construct (Rexin-G) as Monotherapy for Chemo-Resistant Osteosarcoma and Other Sarcomas -- Phase I/II and Phase II Studies;** *2009 ASCO Annual Meeting. May 30, 2009. Abstract #10513. J Clin Oncol 27:15s, 2009.* Authors: Chawla S.P., Chua V.S., Fernandez L., Quon D., Saralou A., Blackwelder W.C., Hall F.L., Gordon E.M.
- 75. Denosumab for the Treatment of Giant Cell Tumor (GCT) of Bone: Final results from a Proof-of-Concept, Phase 2 Study.** 2004015 study. *2009 ASCO Annual Meeting. May 30-June 1, 2009. Abstract #10510. J Clin Oncol 27:15s, 2009.* Authors : Thomas D., Chawla S.P., et al.
- 76. Phase I/II Study of TH-302 Combined with Doxorubicin in Soft Tissue Sarcoma (STS): Preliminary Results.** *Submitted CTOS 2009.* Authors: K.N. Ganjoo, L.D. Cranmer, S. Kroll, V.K. Langmuir, S.P. Chawla.
- 77. Preliminary characterization of oral lesions associated with inhibitors of mammalian target of rapamycin (mTOR) in cancer patients.** *Cancer. Submitted February 25, 2009.* Authors: Sonis S., Treister N., Chawla S.P., Demetri G., Haluska F.
- 78. A study of Palifosfamide in Combination with Doxorubicin: Safety and Preliminary Efficacy;** CTOS 2008. IPM 1002 Study. *November 13-15, 2008. Abstract # 35011.* Authors: S.P. Chawla, L. Camacho, V.S. Chua, G. Abbadessa, B. Schwarz.
- 79. Phase I/II Study of Targeted Gene Delivery In Vivo – Intravenous Infusion of Pathotropic Nanoparticles bearing a Cytocidal Cyclin G1 Construct (Rexin-G) – Demonstrates Anti- Tumor Activity in Chemo-Resistant Metastatic Bone and Soft Tissue Sarcoma.** *CTOS 2008. C07-103, C07-110 Study. November 13-15, 2008. Abstract # 34963.* Authors: V.S. Chua, S.P. Chawla, A. Kalra, D. Quon, K. Beltran, A Saralou, K.Y. Kita, E.M. Gordon, F.L. Hall.
- 80. Phase II Study of Pathotropic Nanoparticles Bearing a Cytocidal Cyclin G1 Construct (Rexin-G) Reveals Significant Anti-Tumor Activity with No Toxicity in Chemo-Resistant Metastatic Osteosarcoma;** CTOS 2008. C07-110 Study. *November 13-15, 2008. Abstract # 34960.* Authors: S.P. Chawla, V.S. Chua, A. Kalra, D. Quon, K. Beltran, A. Saralou, K.Y. Kita, F.L Hall, E.M. Gordon.
- 81. A Phase 1b Open-label Study of AMG 655 in Combination with Doxorubicin for the First- line Treatment of Patients with Locally Advanced or Metastatic, Unresectable Soft Tissue Sarcoma;**

CTOS 2008. 20060324 study. *November 13-15, 2008. Abstract # 34845.* Authors: J.Y. Blay, S Chawla, et al.

82. Initial Results of a Phase II Study of the Safety and Efficacy of the Apomab DR5 Agonist Antibody in Advanced Chondrosarcoma and Synovial Sarcoma Patients; CTOS 2008. APM 4171G Study. *November 12-15, 2008. Abstract # 35010.* Authors: S Chawla, et al.

83. Updated results of Phase II study of trabectedin (ET-743) in pretreated patients with advanced/metastatic soft tissue sarcoma from a single institute. *Proceedings of ASCO 2008, Volume 26, Abstract # 21506.* Authors: V. Mohan, T. Chawla, K. Alzawahereh, W. Jeong, K.Y.Kita, V.S. Chua, A. Kalra, G.S. Rana, S.P. Chawla.

84. Phase I multicenter trial of perifosine in combination with sorafenib for patients with advanced cancers including renal cell carcinoma. *Proceedings of ASCO 2008, Volume 26, Abstract # 16024.* Authors: M. T. Schreeder, R.A. Figlin, J.J. Stephenson, L. Campos, S.P. Chawla, D.R. Spigel, A. Spira, P. Sportelli, L. Gardner, R. Birch, I.C. Henderson.

85. Phase I report from a multicenter trial of perifosine (PERI) + sunitinib (SUT) in patients with advanced cancers including renal cell carcinoma (RCC). *Proceedings of ASCO 2008, Volume 26, Abstract # 14565.* Authors: J.P. Allerton, B. Ebrahimi, M. T. Schreeder, P. Kaiser, S.P. Chawla, P. Sportelli, L. Gardner, R. Birch, I.C. Henderson.

86. Phase I/II study of targeted gene delivery in vivo – intravenous infusions of Rexin-G – demonstrate significant biologic activity by FDG PET-CT without toxicity in patients with progressive chemo-resistant sarcoma, breast cancer, and pancreatic cancer. *Proceedings of ASCO 2008, Volume 26, Abstract # 14509.* Authors: S.P. Chawla, V.S. Chua, V. Mohan, K. Alzawahereh, A. Kalra, D. Quon, E.M. Gordon, F.L. Hall.

87. Denosumab treatment of giant cell tumor of bone: Interim analysis of an open-label phase II study. *Proceedings of ASCO 2008, Volume 26, Abstract # 10500.* Authors: D. Thomas, S.P. Chawla, K. Skubitz, A.P.Staddon, R. Henshaw, J.Y. Blay, J. Smith, Z. Ye, M. Roudier, S. Jun.

88. Assessing the Clinical Impact of Trabectedin in Patients with Leiomyosarcoma or Liposarcoma (L- sarcomas) Progressing Despite Prior Conventional Chemotherapy: Clinical Benefit Rate, Growth Modulation Index and Tumor Variation as Parameters of Treatment Effect in a Randomized International Trial of Two Trabectedin Dosing Regimens. *ASCO-Journal of Clinical Oncology. Vol 25, No. 18S (June 20, 2007 Supplement), 2007: 10060.* Authors: Cesne A. L., Mehren M. V., Chawla S.P., et al.

89. Post-Ifosfamide therapy inflammation in musculoskeletal and soft-tissue sarcomas: Evaluation with F-18 FDG PET and PET/CT. *Proceedings of 2006 SNM 53rd Annual Meeting, Pub. No. 1358, Ref. # 222045.* Authors: Lagaru, R. Masamed, K.K. Sankhala, S.P. Chawla, L. Menendez, A. Fedenko and P.S. Conti, et al.

90. CHOP and Radiation: An Effective Therapy for Primary Lymphoma of the Bone. *Proceedings of ASCO, 2003; Abstract # 2487.* Authors: S.P. Chawla, E.W. Brien, R. Bhuva, L. Menendez, et al.

Sant P. Chawla, M.D.

- 91. Aprepitant 052 and 054 Study Groups.** *Proceedings of ASCO 2003, Volume 22, Abstract # 2919.* Authors: D. Warr, R.J. Gralla, P.J. Hesketh, S.P. Chawla, et al.
- 92. Newer Antiemetic and NK Inhibitor.** *Proceedings of American Society of Clinical Oncology, Vol. 20, Abstract #1527, 2001.* Authors: S. Chawla, et al.
- 93. Successful Treatment of Multiple Myeloma Relapsed After High Dose Chemotherapy With Non-Myeloablative Stem Cell Transplant.** UCLA Medical Center, Los Angeles, CA. *American Society of Clinical Oncology Official Abstract #144, 1999.* Authors: C. Emmanouilides, B. Vescio, S. Chawla, J. Berenson, M. Territo, G. Schiller.
- 94. Systemic Irinotecan (CPT-11) and Regional Chemotherapy Prolong Survival After Hepatic Cryosurgery in Patients With Metastatic Colon Cancer Refractory to 5-Fluorouracil (5-FU).** John Wayne Cancer Institute at Saint John's Health Center, Santa Monica, CA and Century City Hospital, Los Angeles, CA. *American Society of Clinical Oncology Official Abstract #975, 1999.* Authors: J. Bilchik, S. Chawla, D. M. Rose, S. Stern, K. P. Ramming.
- 95. Role of Alfa-Interferon in Reducing Risk of Metastasis in Patients With Poor Prognosis Osteosarcoma.** Orthopedic Hospital, Los Angeles, CA, UCLA School of Medicine, Los Angeles, CA, USC School of Medicine, Los Angeles, CA and Century City Hospital, Los Angeles, CA. *1999 Annual Meeting of the American Society of Clinical Oncology, Abstract #151092.* Authors: S.P. Chawla, V. S. Chua, P. Bauer, T. Ganim, L. Menendez, E. Brien, J. Eckardt and F. Eilber.
- 96. Cryosurgical Ablation of Soft Tissue Sarcomas: A Phase 1 Study of Feasibility and Safety.** *9th International Society of Limb Salvage, September 10-12, 1997, New York, New York.* Authors: L. R. Menendez, Matthew Tan, Milton Kiyabu and Sant P. Chawla.
- 97. A Multiple Marker RT-PCR Assay for Detection of Occult Metastasis in Frozen Sections of Sentinel Nodes from Breast Cancer Patients.** Joyce Eisenberg Keefer Breast Center, Santa Monica, CA and the National Genetics Institute, Los Angeles, CA. *Proceedings of American Society of Clinical Oncology, Vol. 16, 536, 1997.* Authors: P. Bostick, T. Sarantou, K. Huynh, A. Conrad, S.P. Chawla, A. Guiliano and D. Hoon.
- 98. Efficacy and Safety of Oral Granisetron versus IV Ondansetron in Prevention of Moderately Emetogenic Chemotherapy-induced Nausea and Vomiting.** Mayo Clinic, Jacksonville, FL, UCLA School of Medicine, Santa Monica, CA, Oncology and Hematology Group of South Florida, Miami, FL; Smith Kline Beecham Pharmaceuticals, Collegeville, PA. *Proceedings of ASCO, Vol. 16, 149, 1997.* Authors: E. Perez, S.P. Chawla, P. K. Kaywin, etc.
- 99. The Value of Ifosfamide in Postoperative Neoadjuvant Chemotherapy of Osteosarcoma.** *Proceedings of American Society of Clinical Oncology, vol 14, pp 516, #1690, 1995.* Authors: Benjamin R. S., Patel S. R., Armen T., Carrasco C. H., Raymond A. K., Ayala a. G., Chawla S.P., Yasko A. W. and Murray J.
- 100. Chemosensitivity for Malignant Melanoma Correlated With Clinical Response: Identification of a Subgroup of Patients Unlikely to Respond to Chemotherapy.** John Wayne Cancer Institute, Saint John's Hospital and Health Center, Santa Monica, CA 90404. *Proceedings of American Society of*

Sant P. Chawla, M.D.

Clinical Oncology, vol 13, pp 398, #1358, 1994. Authors: Barth A., Cabot M., Chawla S.P., Boasberg P., Foshag L., Gotis J. and Morton D. L.

101. Response to Chemotherapy in Melanoma Patients After Active Specific Immunotherapy (ASI) with Melanoma Cell Vaccine (MCV). John Wayne Cancer Institute, Saint John's Hospital and Health Center, Santa Monica, CA 90404. *Proceedings of American Society of Clinical Oncology*, vol 12, pp 396, #1355, 1993. Authors: Foshag L. J., Morton D. L., Nizze J. A. and Chawla S.P.

102. Primary Chemotherapy of Osteosarcoma of the Extremities - Long Term Follow-up. *Proceedings of American Society of Clinical Oncology*, vol 12, pp 470, #1639, 1993. Authors: Benjamin R. S., Patel S. R., Armen T., Carrasco C. H., Raymond A. K., Ayala A. G., Chawla S.P. and Murray J.

103. High Dose Ifosfamide therapy in Metastatic Soft Tissue Sarcoma. *Proceedings American Association for Cancer Research*, vol 30, 1990. Authors: Chawla S.P., Rosen G., Lowenbraun S., Morton D. and Eilber F.

104. Role of Adriamycin and Cisplatin in therapy of Soft Tissue Sarcomas. *6th International Conference of Adjuvant therapy of Cancer, March 7-11. Tucson, Arizona, 1990.* Authors: Chawla S.P., Rosen G., Lowenbraun S., Morton D. and Eilber F.

105. Role of High Dose Ifosfamide in Recurrent Osteosarcoma. *Proceedings of American Society of Clinical Oncology*, #1210, vol 9, pp 310, 1990. Authors: Chawla S.P., Rosen G., Lowenbraun S., Morton D. and Eilber F.

106. Phase II Study of High Dose Continuous Infusion of Dimethyl Traizeno Imidazole Carboxamide (DTIC) in Metastatic Leiomyosarcoma. *Proceedings American Society of Clinical Oncology*, #1210, vol 9, pp 313, 1990. Authors: Rosen G., Chawla S.P., Hamburg S. and Lowenbraun S.

107. Effects of Recombinant Human Granulocyte macrophage Colony Stimulating Factor (GM-CSF) on chemotherapy-induced Myelosuppression in Patients with Sarcoma. *Proceedings American Society of Clinical Oncology*, #1254, vol 8, pp 322, 1989. Authors: Vadhan-Raj S., Fenoglio C., Chawla S.P., Broxmeyer H. E., Gutterman J. U. and Benjamin R. S.

108. Primary Chemotherapy of Osteosarcoma of the Extremities with systemic Adriamycin and Intra Arterial Cisplatinum. *Proceedings American Society of Clinical Oncology*, vol 8, #1251, pp 322, 1989. Authors: Benjamin R. S., Raymond A. K., Carrasco C. H., Chawla S.P., Armen T., Ayala A. G. and Murray J.

109. Recovery of Sperm Production after chemotherapy with Adriamycin and Cisplatinum. *IV International Congress of Andrology, 1989.* Authors: Meistrich M. L., Chawla S.P. and DaCunha M. F.

110. Optimizing Management of Primary Bone Tumors: An International Symposium Emphasizing the Multi-disciplinary Approach. *Sponsored by the University of Texas MD Anderson Cancer Center, November, 1988.* Authors: Geopfert H., Spires J. R., Raymond A. K. and Chawla S.P.: Osteosarcoma of the Head and Neck. 32nd Annual Clinical Conference and 21st Annual Special Pathology Program.

111. Cisplatin and Adriamycin as therapy for malignant fibrous histiocytoma of bone. 32nd Annual Clinical Conference and 21st Annual Special Pathology Program. Optimizing Management of Primary Bone Tumors: An International Symposium Emphasizing the Multi-disciplinary Approach. *Sponsored by*

Sant P. Chawla, M.D.

the University of Texas MD Anderson Cancer Center, November, 1988. Authors: Chawla S.P., Benjamin R. S., Raymond A. K., Ayala A. G. and Murray J.

112. Telangiectatic Osteosarcoma: Response to Chemotherapy and Limb Salvage. 32nd Annual Clinical Conference and 21st Annual Special Pathology Program. Optimizing Management of Primary Bone Tumors: An International Symposium Emphasizing the Multi-disciplinary Approach. *Sponsored by the University of Texas MD Anderson Cancer Center, November, 1988.* Authors: Chawla S.P., Raymond A. K., Carrasco C. H., Ayala A. G., Murray J. and Benjamin R. S.

113. Evaluation of a Triple Drug Regimen containing Cisplatin (C), Vinblastine and DTIC in patients with Metastatic melanoma. *Proceedings of American Society of Clinical Oncology. Vol. 7, pp 250, #968, 1988.* Authors: Legha S., Ring S., Plager C., Papadopoulos N. E. J., Chawla S.P. and Benjamin R. S.

114. A Randomized study of Carboplatin vs. Continuous Infusion of 5-Fluorouracil in Refractory Epithelial Ovarian Cancer. *Proceedings of American Society of Clinical Oncology. Vol. 7, pp 148, # 572, 1988.* Authors: Chawla S.P., Gershenson D., Freedman R. S., Raber M., Gorski C., Kavanagh J., Smaldone L. and Wharton J. T.

115. Chemotherapy of the Osteosarcoma of the Pelvis. *Proceedings of American Association for Cancer Research #885, pp 223, vol. 29, 1988.* Authors: Paredes J., Chawla S.P., Raymond A. K., Carrasco C. H., Romsdahl N. M., Richli T. A. and Benjamin R. S.

116. Pulmonary Toxicity and Limited Activity of Trimetrexate in Recurrent Carcinoma of Uterine Cervix. *Proceedings of American Association for Cancer Research #823, pp 207, vol 29, 1988.* Authors: Chawla S.P., Kavanagh J. J., Freedman R. S., Raber M., Gershenson D., Edwards C. and Wharton T. J.

117. Osteosarcoma Chemotherapy Effect: A Prognostic Factor. *Sem Diag Path 4:212-236, 1987.* Authors: Raymond A. K., Chawla S.P., Carrasco C. H., Ayala A. G., Fanning C. V., Grive B., Armen T., Plager C., Papadopoulos N. E. J., Edeiken J., Wallace S., Jaffe N., Murray J. A., and Benjamin R. S.

118. Aberrant expression on N-MYC and C-K-RAS as well as overall expression of C-SIS in fresh uncultured human melanoma/sarcoma. *American Association of Cancer Research 28:20, 1987.* Authors: Shin D. M., Gupta V., Chawla S.P., Donner L., Gutterman J. and Blick M.

118. Sequential use of vincristine (V), DTIC (D) and hydroxyurea (H) in advanced malignant melanoma. *American Society of Clinical Oncology 6:129, 1987.* Authors: Papadopoulos N. E. J., Ring S., Plager C., Legha S., Chawla S.P. and Benjamin R. S.

120. Evaluation of intravenous (IV) N-acetylcysteine (NAC) as an un-protector against Ifosfamide (IFF) toxicity in patients with advanced sarcomas. *American Society of Clinical Oncology 6:129, 1987.* Authors: Legha S., Fitz K., Papadopoulos N. E. J., Chawla S.P., Plager C. and Benjamin R. S.

121. Arteriographic prediction of tumor necrosis after primary treatment of osteosarcoma in adults. *American Society of Clinical Oncology 6:129, 1987.* Authors: Carrasco C. H., Chawla S.P., Benjamin R. S., Raymond A. K., Ayala A. G., Murray J. and Wallace S.

- 122. Ifosfamide (IFF) therapy for progressive pretreated metastatic sarcoma via compassionate IND.** *American Society of Clinical Oncology 6:128, 1987.* Authors: Plager C., Papadopoulos N. E. J., Chawla S.P., Sandberg S., Legha S. and Benjamin R. S.
- 123. Preoperative Intra-arterial Cisplatin and Limb Salvage Surgery for Patients with High Grade Osteosarcoma of the Extremities.** *5th International Conference of the Adjuvant Therapy of Cancer. Tucson, Arizona, March, 1987.* Authors: Chawla S.P., Benjamin R. S., Jaffe N., Carrasco C. H., Raymond A. K., Ayala A., Wallace S., Armen T., Papadopoulos N. E. J., Plager C. and Murray J.
- 124. Adjuvant Immunotherapy of MD Anderson Stage III-B Malignant Melanoma.** *5th International Conference of the Adjuvant therapy for Cancer. Tucson, Arizona, March 11-14, 1987.* Authors: Plager C., Bowen J. M., Fenoglio C. J., Papadopoulos N. E. J., Murray J., Chawla S.P., Benjamin R. S., Savage H. E., Rosen R. P. and Hersh E. M.
- 125. Angiographic evaluation of response to preoperative chemotherapy in osteosarcoma.** *72nd Scientific Assembly of the Radiological Society of north America, 1986.* Authors: Carrasco C. H., Charnasangavej C., Richli W., Wallace S., Chawla S.P., Raymond A. K., Murray J. and Benjamin R. S.
- 126. Role of chemotherapy in potential cure and limb salvage of high grade osteosarcoma of extremity.** *Indian Society of Oncology, 2nd Biennial Conference. Feb. 9-14, 1986, pp 165, 1986.* Authors: Chawla S.P., Benjamin R. S., Raymond A. K., Carrasco C. H., Wallace S., Murray J. and Ayala A.
- 127. Clinical efficacy of Roferon-A in metastatic melanoma: A comparison to two dose schedules.** *American Society of Clinical Oncology 4:228, 1986.* Authors: Legha S., Pickett S., Plager C., Papadopoulos N. E. J., Chawla S.P., Itri L. and Benjamin R. S.
- 128. Primary chemotherapy of patients with osteosarcoma of an extremity.** *American Society of Clinical Oncology 4:139, 1986.* Authors: Benjamin R.S., Chawla S.P., Carrasco C. H., Raymond A. K., Wallace S., Murray J., Ayala A. and Romsdahl M.
- 129. Osteosarcoma, preoperative chemotherapy: histological evaluation.** *American Society of Clinical Oncology 4:138, 1986.* Authors: Raymond A. K., Benjamin R. S., Carrasco C. H., Ayala A., Chawla S.P., Wallace S. and Murray J.
- 130. Malignant fibrous histiocytoma of the head and neck.** *American Society of Clinical Oncology 4:138, 1986.* Authors: Kramer A., Fayssoux F., Atkinson E. N., Chawla S.P., Byers R., Goepfert H., Dimery I. and Hong W. K.,
- 131. Adjuvant Immunotherapy with Newcastle disease virus oncolysate of MD Anderson state III-B malignant melanoma.** *American Society of Clinical Oncology 4:138, 1986.* Authors: Plager C., Bowen J. M., Fenoglio C., Papadopoulos N. E. J., Murray L., Chawla S.P., Benjamin R. S., Savage H. E., Rosen R. D. and Hersh E. M.
- 132. High dose intravenous cytoxan, carmustine, etoposide and autologous bone marrow transplant for advanced refractory small round cell sarcomas in adults.** *American Society of Clinical Oncology. 4:137, 1986.* Authors: Papadopoulos N. E. J., Armen T., Chawla, S.P., Horwitz L., Spitzer G., Dicke K., Plager C. and Benjamin R. S.

- 133. Decreased cardiotoxicity of 96-hour continuous infusion adriamycin compared with Epirubicin.** *American Society of Clinical Oncology* 4:44, 1986. Authors: Chawla S.P., Benjamin R. S., Hortobagyi G. N., Ajani J. A. and Body G. P.
- 134. Curative and limb-saving role of intra-arterial cis-platinum and systemic adriamycin in osteosarcoma.** *American Association for cancer Research.* 27:182, 1986. Authors: Chawla S.P., Benjamin R. S., Ayala A. G., Raymond A. J., Armen T., Carrasco C. H., Wallace S., Papadopoulos N. E. J., Plager C., Romsdahl M. M., Richli W. R. and Murray J.
- 135. The cardiotoxicity of chemotherapeutic agents: evaluation by endomyocardial biopsy and nuclear Angiographic ejection fraction.** *14th International Congress of Chemotherapy, Kyoto, Japan, June, 1985.* Authors: Benjamin R. S., Chawla S.P., Ewer M. S., Carrasco C. H. and Mackay B.
- 136. Correlation of ejection fractions and biopsy grades in patients receiving adriamycin.** *14th International Congress of Chemotherapy, Kyoto, Japan, June, 1985.* Authors: Ewer M. S., Chawla S.P., Carrasco C. H., Mackay B., Ali M. K., Haynie III T. P. and Benjamin R. S.
- 137. Prognostically directed preoperative and postoperative chemotherapy and limb salvage surgery of high grade osteosarcoma.** *14th International Congress of Chemotherapy, Kyoto, Japan, June, 1985.* Authors: Chawla S.P., Benjamin R. S., Carrasco C. H., Raymond A. G., Papadopoulos N. E. J., Plager C. and Murray J. A.
- 138. High rates of complete remission, limb salvage and prolonged survival in telangiectatic osteosarcoma after preoperative chemotherapy with intra-arterial cisplatinum and systemic adriamycin.** *American Society of Clinical Oncology* 4:152, 1985. Authors: Chawla S.P., Raymond A. K., Carrasco C. H., Papadopoulos N. E. J., Plager C., Romsdahl N. M., Ayala A. G., Wallace S., Murray J. A., Bodey G. P. and Benjamin R. S.
- 139. High Dose intravenous melphalan, carmustine, etoposide and bone marrow transplant for advanced refractory malignancy.** *American Society of Clinical Oncology* 4:151, 1985. Authors: Papadopoulos N. E. J., Fayssoux R., Vellekoop L., Chawla S.P., Plager C., Spitzer G. and Benjamin R. S.
- 140. Adjuvant immunotherapy with Newcastle disease virus oncolysate of MD Anderson state III-B malignant melanoma.** *American Society of Clinical Oncology* 4:151, 1985. Authors: Plager C., Bowen J. M., Fenoglio C., Papadopoulos N. E. J., Murray L., Chawla S.P., Benjamin R. S. and Hersh E. M.
- 141. A comparison of resting and exercise ejection.** *American Society of Clinical Oncology* 4:150, 1985. Authors: Ewer M. S., Ali M. K., Chawla S.P., Carrasco C. H., Lamki L., Mackay B., Balakrishnan P. V., Johnston D. A. and Benjamin R. S.
- 142. Phase II study of bisantrene in advanced malignant melanoma.** *American Association of Cancer Research.* 26:174, 1985. Authors: Papadopoulos N. E. J., Tenney D. M., Chawla S.P., Plager C. and Benjamin R. S.
- 143. Response to preoperative chemotherapy of osteosarcoma improves disease-free survival and the chances of limb salvage.** *American Association for Cancer Research.* 26:174, 1985. Authors: Benjamin R. S., Chawla S.P., Murray J. A., Carrasco C. H., Raymond A. K., Ayala A., Wallace S., Romsdahl M. M., Plager C. and Papadopoulos N. E. J.

144. Sperm production following chemotherapy for sarcomas. *American Association for Cancer Research. 26:170, 1985.* Authors: Meistrich M. L., deCunha M. F., Chawla S.P., Plager C., Papadopoulos N. E. J. and Benjamin R. S.

145. Chemotherapy of primary osteosarcoma - A study of prognostic factors. *4th International Conference of the Adjuvant Therapy of Cancer. Tucson, Arizona, March 21-24, 1984.* Authors: Benjamin R. S., Chawla S.P., Murray J. A., Wallace S., Carrasco C. H., Ayala A., Raymond A. K., Romsdahl M., Plager C. and Papadopoulos N. E. J.

146. Adjuvant chemotherapy of primary malignant fibrous histiocytoma (MFH) of bone. *4th International Conference of Adjuvant Therapy of Cancer. Tucson, Arizona, March 21- 24, 1984.* Authors: Chawla S.P., Benjamin R. S., Ayala A. G., Evans H., Papadopoulos N. E. J., Plager C., Jaffe N. and Murray J. A.

147. Phase II study of Bisantrene in advanced sarcoma. *American Society of Clinical Oncology 3:263, 1984.* Authors: Papadopoulos N. E. J., Tenney D. M., Benjamin R. S., Plager C., Chawla S.P. and Bodey G. P.

148. Detorubicin - an active anthracycline in metastatic melanoma. *American Society of Clinical Oncology 3:263, 1984.* Authors: Chawla S.P., Benjamin R. S., Legha S., Plager C., Papadopoulos N. E. J., Ewer M. S., Mackay B., Bodey G. P. and Wang A.

149. A review of epithelioid sarcoma. *American Society of Clinical Oncology 3: 262, 1984.* Authors: Plager C., Papadopoulos N. E. J., Chawla S.P., Ayala A. G., Yap B. S., Romsdahl M. M., Martin R. G., Cangir A., Lindberg R. D., and Benjamin R. S.

150. Evaluation of Mitoxantrone cardiac toxicity by nuclear angiography and endomyocardial biopsy. *American Society of Clinical Oncology 3:40, 1984.* Authors: Benjamin R. S., Chawla S.P., Ewer M. S., Carrasco C. H., Mackay B., Haynie III T. P., Yap H. Y., Blumenschein G. R., Holmes F., Ali M. K. and Bodey G. P.

151. Clinical pharmacology of homoharringtonine (HHT). *ASCO: 38, 1984.* Authors: Savaraj N., Lu K., Dimery I., Feun L., Burgess M. A. Guo Z., Chawla S.P. and Loo T. L.

152. Phase II study of combination of 4-9 acridinylomino methanosulfon-M-anisidide (AMSA) and cis-platinum diamino-dichloride cisplatin (CDDP) in the treatment of adult acute leukemia (ALL). *American Society of Clinical Oncology 2:172, 1983.* Authors: Chawla S.P., McCredie K. B., Keating M. J., Estey E., Walters R. S., Bodey G. P., and Freireich E. J.

153. Cardiac toxicity of high cumulative dose adriamycin by rapid or 24-96 hour continuous infusion. *American Society of Clinical Oncology 2:40, 1983.* Authors: Benjamin R. S., Chawla S.P., Ewer M. S., Wallace S. R., Mackay B., Carrasco C. H., Legha S. S., Mann G., Hortobagyi G. N., Valdivieso M., Ali M. K., and Haynie T. P.

154. Primary malignant fibrous histiocytoma of bone - A chemotherapy responsive tumor. *American Association for Cancer Research 24:144, 1983.* Authors: Benjamin R. S., Chawla S.P., Plager P., Papadopoulos N. E., Yap B., Ayala A. G., Wallace S. R., Saunders P. P. And Murray JA.

Sant P. Chawla, M.D.

155. Monitoring of adriamycin cardiotoxicity beyond the conventional limits of 500 mg/m².

American Association of Cancer Research 24:134, 1983. Authors: Chawla S.P., Mann G. Benjamin R. S., Legha S. S., Mackay B., Ewer M. S., Ali M. K., Carrasco C. H., Hortobagyi G. N., Wallace S. R., Valdivieso M., Kim E. E., and Haynie T. P.

Poster Presentations

1. A Phase 2 Study of CMB305 and Atezolizumab in NY-ESO-1+ Soft Tissue Sarcoma: Interim Analysis of Immunogenicity, Tumor Control and Survival. S. Chawla; B.A. Van Tine, Me; S.M.

Pollack, Med; K. Ganjoo; A. Elias; R. Riedel; S. Attia; E. Choy; S. Okuno; M. Agulnik; M. von Mehren, M. Livingston; V. Keedy; C. Verschraegen; R. Maki. *CTOS 2017 Annual Meeting Maui, Hawaii, November 8 – 11, 2017.*

2. Cancer Immunotherapy Using Trabectedin and Nivolumab in Advanced Soft Tissue Sarcoma: A Retrospective Analysis. Sant Chawla ; Kamalesh Sankhala ; Stumpf Nathan ; Seth Kim ; Susan

Arasheben ; Leong Bryan ; Grace Kang ; William W. Tseng ; Erlinda M. Gordon, *CTOS 2017 Annual Meeting, Maui, Hawaii, November 8 – 11, 2017.*

3. Preliminary Evidence of Clinical Response to Entrectenib in Three Sarcoma Patients. P. Multani,

E. Chow Manavel, Z. Hornby, S.J. Potts, P.J. Foley, Ignyta, Inc., San Diego, California, USA; S. Chawla, V.S. Chua, K. Kim, L. Bryan, E.M. Gordon, D. Quon, K. Sankhala. *CTOS 2017 Annual Meeting, Maui, Hawaii, November 8 – 11, 2017.*

4. Association of NY-ESO-1 Expression With Baseline Immunity and Clinical Outcomes in Soft Tissue Sarcoma (STS) Patients (PTS) treated with LV305 or CMB305. S.M. Pollack; S. Chawla; M.

Druta; K. Do; J. Kim; N. Somaiah ; M. Block ; C. Bohac, M. Chen; H. Lu., *CTOS 2017 Annual Meeting, Maui, Hawaii, November 8 – 11, 2017.*

5. Sequence -Specific Antibodies for Identification, Capture and Characterization of Circulating Sarcoma Cells and Cells Undergoing Epithelial to mesenchymal Transition. E.M. Gordon, S.

Chawla; P. Pagano, W. Strauss, P. Dempsey, P. Song, R. Reed; F. Hall. *CTOS 2017 Annual Meeting, Maui, Hawaii, November 8 – 11, 2017.*

6. Phase II Multi-Center, Randomized Trial of Gemcitabine with Pazopanib or Gemcitabine with Docetaxel in Previously Treated Subjects with Advanced Soft Tissue sarcoma. N. Somaiah, A.P.

Conley; B.A. Van Tine; M. Milhem; E. Garrett-Mayer, J. Kim, D. Reuben; S. Schuetze; C.F. Meyer; A. Elias; W. Read; S. Chawla; A. Kraft. *CTOS 2017 Annual Meeting, Maui, Hawaii, November 8 – 11, 2017.*

7. Safety and Efficacy of Denosumab in Patients with Giant Cell Tumor of Bone: Results of an Open-Label Phase 2 Study. A. Feng, D. Jandial; S. Ferrari; J. Blay; P. Reichardt; P. Rutkowski; R.

Henshaw; R.J. Grimer; S. Chawla. *CTOS 2017 Annual Meeting, Maui, Hawaii, November 8 – 11, 2017.*

Sant P. Chawla, M.D.

8. Subtype-specific Activity in Liposarcoma (LPS) patients (pts) from a Phase 3, Open-Label, Randomized Study of Eribulin (ERI) Versus Dacarbazine (DTIC) in Patients with Advanced LPS and Leiomyosarcoma (LMS) . *ASCO Annual Meeting, Chicago, June 3-7, 2016.*

9. Long-term Treatment of Giant Cell Tumors of Bone (GCTB) with Denosumab: A Two Institutions 8year Experience. *ASCO Annual Meeting, Chicago, June 3 – 7, 2016*

10. A Study of the Safety and Efficacy of the Combination of Gemcitabine and Docetaxel with Ontuxizumab (MORAb-004) in Metastatic Soft Tissue Sarcoma. *ASCO Annual Meeting Chicago, May 29 – June 2 , 2015*

11. Randomized Phase III Trial of Trabectedin versus Doxorubicin-based Chemotherapy as First Line Therapy in Translocation-Related Sarcomas. *ASCO Annual Meeting, Chicago, May 31-June 4, 2013.* Andrew Hendifar, Sant P. Chawla, Michael Gordon Leahy, Antoine Italiano, Shreyaskumar Patel, Peter Hohenberger, Armando Santoro, Arthur P. Staddon, Nicolas Penel, Sophie Piperno-Neumann, George D. Demetri, Larry Hayward, Jeff White, Launce G. Gouw, Bernardo Miguel-Lillo, Pilar Lardelli, Arturo Soto-Matos, Antonio Nieto, Jean-Yves Blay.

12. 14 Day Continuous Infusion High Dose Ifosfamide in Adolescent and Adult Sarcoma Patients, an Updated Analysis. *CTOS Annual Meeting, Prague, Czech Republic, November 14- 17, 2012.* Harsha Rajashekharaiah, Andrew Hendifar, Victoria Chua, Doris Quon, Lita Fernandez, Kristen Ganjoo, Kamalesh Sankhala, Vivek Narasimhan, David Shin, Monish Sodhi, Alison Bonk, Pritesh Chaudhari, and Sant Chawla.

13. Low Dose Gemcitabine, Doxorubicin, and Docetaxel Combination in Patients with Advanced, Unresectable and/or Metastatic Sarcoma Who had Failed Prior Chemotherapy, an Updated Analysis. *CTOS Annual Meeting, Prague, Czech Republic, November 14-17, 2012.* Vivek Narasimhan, Andrew Hendifar, Victoria Chua, Doris Quon, Lita Fernandez, Harsha Rajashekharaiah, David Shin, Alison Bonk, Monish Sodhi, Pritesh Chaudhari and Sant Chawla.

14. INNO-206 is an active drug for relapsed advanced soft tissue sarcoma. *37th ESMO Congress, Vienna, Austria, September 28 – October 2, 2012.* S. Chawla, V.S. Chua, A. Hendifar, D. Quon, S. Nagre, K.N. Ganjoo, K. Sankhala, Y. Lavinski, S. Wieland, D. Levitt.

15. 14 Day Continuous Infusion High-Dose Ifosfamide in Adolescent and Adult Sarcoma Patients. *ASCO Annual Meeting, Oct, 2011.* Andrew Hendifar, Shelly Chawla, Sandeep Nagre, Vicky Chua, Lita Fernandez, Bartosz Chmielowski, James Hu, and Sant Chawla.

16. A Phase 2 Dose Expansion of TH-302 in combination with Doxorubicin in Advanced soft Tissue Sarcoma. *ASCO Annual Meeting, June 3-7, 2011.* Chawla S.P. et al.